{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:29:19Z","timestamp":1773235759500,"version":"3.50.1"},"reference-count":397,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12035-012-8316-3","type":"journal-article","created":{"date-parts":[[2012,9,3]],"date-time":"2012-09-03T09:54:04Z","timestamp":1346666044000},"page":"430-466","source":"Crossref","is-referenced-by-count":40,"title":["Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II"],"prefix":"10.1007","volume":"46","author":[{"given":"Pawel M.","family":"Switonski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech J.","family":"Szlachcic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Gabka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlodzimierz J.","family":"Krzyzosiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Figiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,4]]},"reference":[{"issue":"9","key":"8316_CR1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","volume":"9","author":"A Durr","year":"2010","unstructured":"Durr A (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9(9):885\u2013894","journal-title":"Lancet Neurol"},{"issue":"1","key":"8316_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83\u201398","journal-title":"Lancet Neurol"},{"issue":"5","key":"8316_CR3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","volume":"5","author":"MF Beal","year":"2004","unstructured":"Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic mouse models of Huntington\u2019s disease. Nat Rev Neurosci 5(5):373\u2013384","journal-title":"Nat Rev Neurosci"},{"key":"8316_CR4","doi-asserted-by":"crossref","unstructured":"Wagner L, Menalled L, Gomeniouk A, Brunner D, Leavitt B (2008) Huntington Disease. Animal and Translational Models for CNS Drug Discovery. Elsevier, pp 207\u2013266","DOI":"10.1016\/B978-0-12-373861-5.00018-7"},{"issue":"6","key":"8316_CR5","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1471-4159.2009.06302.x","volume":"110","author":"PO Bauer","year":"2009","unstructured":"Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110(6):1737\u20131765","journal-title":"J Neurochem"},{"issue":"3","key":"8316_CR6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90(3):905\u2013981","journal-title":"Physiol Rev"},{"key":"8316_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","volume":"30","author":"HT Orr","year":"2007","unstructured":"Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30:575\u2013621","journal-title":"Annu Rev Neurosci"},{"key":"8316_CR8","doi-asserted-by":"crossref","unstructured":"Shao J, Diamond MI (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16 Spec No. 2:R115\u2013123","DOI":"10.1093\/hmg\/ddm213"},{"issue":"12","key":"8316_CR9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbadis.2008.10.002","volume":"1782","author":"NB Nedelsky","year":"2008","unstructured":"Nedelsky NB, Todd PK, Taylor JP (2008) Autophagy and the ubiquitin\u2013proteasome system: collaborators in neuroprotection. Biochim Biophys Acta 1782(12):691\u2013699","journal-title":"Biochim Biophys Acta"},{"issue":"7154","key":"8316_CR10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nature06022","volume":"448","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B, Ryu K-Y, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR (2007) Global changes to the ubiquitin system in Huntington\u2019s disease. Nature 448(7154):704\u2013708","journal-title":"Nature"},{"issue":"5","key":"8316_CR11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nn.2528","volume":"13","author":"M Martinez-Vicente","year":"2010","unstructured":"Martinez-Vicente M, Talloczy Z, Wong E et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington\u2019s disease. Nat Neurosci 13(5):567\u2013576","journal-title":"Nat Neurosci"},{"issue":"19","key":"8316_CR12","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1093\/hmg\/ddq285","volume":"19","author":"MY Heng","year":"2010","unstructured":"Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19(19):3702\u20133720","journal-title":"Hum Mol Genet"},{"issue":"10","key":"8316_CR13","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1523\/JNEUROSCI.5673-09.2010","volume":"30","author":"Z Ortega","year":"2010","unstructured":"Ortega Z, D\u00edaz-Hern\u00e1ndez M, Maynard CJ, Hern\u00e1ndez F, Dantuma NP, Lucas JJ (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin\/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 30(10):3675\u20133688","journal-title":"J Neurosci"},{"issue":"7113","key":"8316_CR14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature05291","volume":"443","author":"DC Rubinsztein","year":"2006","unstructured":"Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443(7113):780\u2013786","journal-title":"Nature"},{"issue":"12","key":"8316_CR15","doi-asserted-by":"crossref","first-page":"a006734","DOI":"10.1101\/cshperspect.a006734","volume":"2","author":"E Wong","year":"2010","unstructured":"Wong E, Cuervo AM (2010) Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harb Perspect Biol 2(12):a006734","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"8316_CR16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585\u2013595","journal-title":"Nat Genet"},{"issue":"Pt 1","key":"8316_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/awp292","volume":"133","author":"FM Menzies","year":"2010","unstructured":"Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133(Pt 1):93\u2013104","journal-title":"Brain"},{"key":"8316_CR18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1326-5-26","volume":"5","author":"JH Fox","year":"2010","unstructured":"Fox JH, Connor T, Chopra V et al (2010) The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6\/2 mouse model of Huntington\u2019s disease. Mol Neurodegener 5:26","journal-title":"Mol Neurodegener"},{"issue":"11","key":"8316_CR19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","volume":"19","author":"C Rose","year":"2010","unstructured":"Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O, Brown SD, Rubinsztein DC (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u2019s disease. Hum Mol Genet 19(11):2144\u20132153","journal-title":"Hum Mol Genet"},{"issue":"4","key":"8316_CR20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/embor.2008.31","volume":"9","author":"T Torashima","year":"2008","unstructured":"Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S, Oue M, Yamaguchi H, Hirai H (2008) Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep 9(4):393\u2013399","journal-title":"EMBO Rep"},{"issue":"19","key":"8316_CR21","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1523\/JNEUROSCI.1242-07.2007","volume":"27","author":"H Adachi","year":"2007","unstructured":"Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G (2007) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 27(19):5115\u20135126","journal-title":"J Neurosci"},{"issue":"20","key":"8316_CR22","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1093\/hmg\/ddn218","volume":"17","author":"HK Wong","year":"2008","unstructured":"Wong HK, Bauer PO, Kurosawa M et al (2008) Blocking acid-sensing ion channel 1 alleviates Huntington\u2019s disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 17(20):3223\u20133235","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8316_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101(1):57\u201366","journal-title":"Cell"},{"issue":"4","key":"8316_CR24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jmcb\/mjq005","volume":"2","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Katada S, Onodera O (2010) Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J Mol Cell Biol 2(4):180\u2013191","journal-title":"J Mol Cell Biol"},{"issue":"30","key":"8316_CR25","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/138161208786404164","volume":"14","author":"Y Nagai","year":"2008","unstructured":"Nagai Y, Popiel HA (2008) Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. Curr Pharm Des 14(30):3267\u20133279","journal-title":"Curr Pharm Des"},{"issue":"6921","key":"8316_CR26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","volume":"421","author":"I S\u00e1nchez","year":"2003","unstructured":"S\u00e1nchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421(6921):373\u2013379","journal-title":"Nature"},{"issue":"2","key":"8316_CR27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","volume":"54","author":"DL Smith","year":"2003","unstructured":"Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, Bates GP, Hockly E (2003) Minocycline and doxycycline are not beneficial in a model of Huntington\u2019s disease. Ann Neurol 54(2):186\u2013196","journal-title":"Ann Neurol"},{"issue":"1","key":"8316_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.expneurol.2004.01.003","volume":"187","author":"G Schilling","year":"2004","unstructured":"Schilling G, Savonenko AV, Coonfield ML et al (2004) Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187(1):137\u2013149","journal-title":"Exp Neurol"},{"issue":"2","key":"8316_CR29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10(2):148\u2013154","journal-title":"Nat Med"},{"issue":"1","key":"8316_CR30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nbd.2005.07.007","volume":"21","author":"E Hockly","year":"2006","unstructured":"Hockly E, Tse J, Barker AL et al (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington\u2019s disease. Neurobiol Dis 21(1):228\u2013236","journal-title":"Neurobiol Dis"},{"issue":"2","key":"8316_CR31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.nbd.2006.09.015","volume":"25","author":"NI Wood","year":"2007","unstructured":"Wood NI, Pallier PN, Wanderer J, Morton AJ (2007) Systemic administration of Congo red does not improve motor or cognitive function in R6\/2 mice. Neurobiol Dis 25(2):342\u2013353","journal-title":"Neurobiol Dis"},{"issue":"42","key":"8316_CR32","doi-asserted-by":"crossref","first-page":"16685","DOI":"10.1073\/pnas.0707842104","volume":"104","author":"V Chopra","year":"2007","unstructured":"Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S (2007) A small-molecule therapeutic lead for Huntington\u2019s disease: preclinical pharmacology and efficacy of C2-8 in the R6\/2 transgenic mouse. Proc Natl Acad Sci U S A 104(42):16685\u201316689","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8316_CR33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jnr.21817","volume":"87","author":"C-R Yang","year":"2009","unstructured":"Yang C-R, Yu RK (2009) Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington\u2019s disease. J Neurosci Res 87(1):26\u201333","journal-title":"J Neurosci Res"},{"issue":"2","key":"8316_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2008.06.015","volume":"449","author":"HA Popiel","year":"2009","unstructured":"Popiel HA, Nagai Y, Fujikake N, Toda T (2009) Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett 449(2):87\u201392","journal-title":"Neurosci Lett"},{"issue":"5","key":"8316_CR35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1083\/jcb.200710158","volume":"181","author":"C-E Wang","year":"2008","unstructured":"Wang C-E, Zhou H, McGuire JR, Cerullo V, Lee B, Li S-H, Li X-J (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 181(5):803\u2013816","journal-title":"J Cell Biol"},{"issue":"43","key":"8316_CR36","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","volume":"29","author":"AL Southwell","year":"2009","unstructured":"Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease. J Neurosci 29(43):13589\u201313602","journal-title":"J Neurosci"},{"issue":"10","key":"8316_CR37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","volume":"69","author":"A Snyder-Keller","year":"2010","unstructured":"Snyder-Keller A, McLear JA, Hathorn T, Messer A (2010) Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice. J Neuropathol Exp Neurol 69(10):1078\u20131085","journal-title":"J Neuropathol Exp Neurol"},{"issue":"17","key":"8316_CR38","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1073\/pnas.170280697","volume":"97","author":"J Carmichael","year":"2000","unstructured":"Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington\u2019s disease. Proc Natl Acad Sci U S A 97(17):9701\u20139705","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8316_CR39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1471-4159.2005.03119.x","volume":"94","author":"TV Novoselova","year":"2005","unstructured":"Novoselova TV, Margulis BA, Novoselov SS, Sapozhnikov AM, van der Spuy J, Cheetham ME, Guzhova IV (2005) Treatment with extracellular HSP70\/HSC70 protein can reduce polyglutamine toxicity and aggregation. J Neurochem 94(3):597\u2013606","journal-title":"J Neurochem"},{"issue":"6","key":"8316_CR40","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1096\/fj.07-099689","volume":"22","author":"JA McLear","year":"2008","unstructured":"McLear JA, Lebrecht D, Messer A, Wolfgang WJ (2008) Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington\u2019s disease. FASEB J 22(6):2003\u20132011","journal-title":"FASEB J"},{"issue":"1\u20132","key":"8316_CR41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0006-8993(02)04275-0","volume":"970","author":"O Hansson","year":"2003","unstructured":"Hansson O, Nylandsted J, Castilho RF, Leist M, J\u00e4\u00e4ttel\u00e4 M, Brundin P (2003) Overexpression of heat shock protein 70 in R6\/2 Huntington\u2019s disease mice has only modest effects on disease progression. Brain Res 970(1\u20132):47\u201357","journal-title":"Brain Res"},{"issue":"22","key":"8316_CR42","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1093\/hmg\/ddi372","volume":"14","author":"C Vacher","year":"2005","unstructured":"Vacher C, Garcia-Oroz L, Rubinsztein DC (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 14(22):3425\u20133433","journal-title":"Hum Mol Genet"},{"issue":"23","key":"8316_CR43","doi-asserted-by":"crossref","first-page":"16027","DOI":"10.1074\/jbc.M710606200","volume":"283","author":"AL Orr","year":"2008","unstructured":"Orr AL, Huang S, Roberts MA, Reed JC, Li S, Li X-J (2008) Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice. J Biol Chem 283(23):16027\u201316036","journal-title":"J Biol Chem"},{"issue":"13","key":"8316_CR44","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/hmg\/ddh144","volume":"13","author":"DG Hay","year":"2004","unstructured":"Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington\u2019s disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13(13):1389\u20131405","journal-title":"Hum Mol Genet"},{"issue":"41","key":"8316_CR45","doi-asserted-by":"crossref","first-page":"34908","DOI":"10.1074\/jbc.M506288200","volume":"280","author":"M Fujimoto","year":"2005","unstructured":"Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A (2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 280(41):34908\u201334916","journal-title":"J Biol Chem"},{"issue":"14","key":"8316_CR46","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/hmg\/10.14.1511","volume":"10","author":"CJ Cummings","year":"2001","unstructured":"Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10(14):1511\u20131518","journal-title":"Hum Mol Genet"},{"issue":"6","key":"8316_CR47","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1523\/JNEUROSCI.23-06-02203.2003","volume":"23","author":"H Adachi","year":"2003","unstructured":"Adachi H, Katsuno M, Minamiyama M et al (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23(6):2203\u20132211","journal-title":"J Neurosci"},{"issue":"46","key":"8316_CR48","doi-asserted-by":"crossref","first-page":"16801","DOI":"10.1073\/pnas.0506249102","volume":"102","author":"M Katsuno","year":"2005","unstructured":"Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 102(46):16801\u201316806","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"8316_CR49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1298","volume":"11","author":"M Waza","year":"2005","unstructured":"Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11(10):1088\u20131095","journal-title":"Nat Med"},{"issue":"5","key":"8316_CR50","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/hmg\/ddn419","volume":"18","author":"K Tokui","year":"2009","unstructured":"Tokui K, Adachi H, Waza M et al (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 18(5):898\u2013910","journal-title":"Hum Mol Genet"},{"key":"8316_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1423-0127-18-10","volume":"18","author":"NM Jensen","year":"2011","unstructured":"Jensen NM, Dalsgaard T, Jakobsen M, Nielsen RR, S\u00f8rensen CB, Bolund L, Jensen TG (2011) An update on targeted gene repair in mammalian cells: methods and mechanisms. J Biomed Sci 18:10","journal-title":"J Biomed Sci"},{"issue":"8","key":"8316_CR52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","volume":"10","author":"H Xia","year":"2004","unstructured":"Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10(8):816\u2013820","journal-title":"Nat Med"},{"issue":"16","key":"8316_CR53","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci USA 102(16):5820\u20135825","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"8316_CR54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol Ther 12(4):618\u2013633","journal-title":"Mol Ther"},{"issue":"3","key":"8316_CR55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"Y-L Wang","year":"2005","unstructured":"Wang Y-L, Liu W, Wada E, Murata M, Wada K, Kanazawa I (2005) Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci Res 53(3):241\u2013249","journal-title":"Neurosci Res"},{"issue":"1","key":"8316_CR56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Y Machida","year":"2006","unstructured":"Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 343(1):190\u2013197","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"8316_CR57","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther 17(6):1053\u20131063","journal-title":"Mol Ther"},{"issue":"3","key":"8316_CR58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65(3):276\u2013285","journal-title":"Ann Neurol"},{"issue":"3","key":"8316_CR59","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","volume":"362","author":"I Schmitt","year":"2007","unstructured":"Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, Wuellner U (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 362(3):734\u2013739","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"8316_CR60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12017-010-8137-3","volume":"13","author":"PM Switonski","year":"2011","unstructured":"Switonski PM, Fiszer A, Kazmierska K, Kurpisz M, Krzyzosiak WJ, Figiel M (2011) Mouse ataxin-3 functional knock-out model. Neuromolecular Med 13(1):54\u201365","journal-title":"Neuromolecular Med"},{"issue":"9","key":"8316_CR61","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel J-P, Zamore PD, Aronin N (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19(9):774\u2013778","journal-title":"Curr Biol"},{"issue":"12","key":"8316_CR62","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","volume":"100","author":"VM Miller","year":"2003","unstructured":"Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paulson HL (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100(12):7195\u20137200","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"8316_CR63","doi-asserted-by":"crossref","first-page":"e3341","DOI":"10.1371\/journal.pone.0003341","volume":"3","author":"S Alves","year":"2008","unstructured":"Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, D\u00e9glon N (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3(10):e3341","journal-title":"PLoS One"},{"issue":"13","key":"8316_CR64","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1093\/nar\/gkr156","volume":"39","author":"A Fiszer","year":"2011","unstructured":"Fiszer A, Mykowska A, Krzyzosiak WJ (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 39(13):5578\u201385","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"8316_CR65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","volume":"27","author":"J Hu","year":"2009","unstructured":"Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27(5):478\u2013484","journal-title":"Nat Biotechnol"},{"issue":"11","key":"8316_CR66","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","volume":"17","author":"J Hu","year":"2010","unstructured":"Hu J, Liu J, Corey DR (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 17(11):1183\u20131188","journal-title":"Chem Biol"},{"issue":"19","key":"8316_CR67","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/hmg\/ddr299","volume":"20","author":"M Wojciechowska","year":"2011","unstructured":"Wojciechowska M, Krzyzosiak WJ (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 20(19):3811\u20133821","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8316_CR68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/nar\/gkr729","volume":"40","author":"WJ Krzyzosiak","year":"2012","unstructured":"Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P (2012) Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res 40(1):11\u201326","journal-title":"Nucleic Acids Res"},{"key":"8316_CR69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0079-6123(10)84013-0","volume":"184","author":"SB Rangasamy","year":"2010","unstructured":"Rangasamy SB, Soderstrom K, Bakay RAE, Kordower JH (2010) Neurotrophic factor therapy for Parkinson\u2019s disease. Prog Brain Res 184:237\u2013264","journal-title":"Prog Brain Res"},{"issue":"3","key":"8316_CR70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrd3366","volume":"10","author":"AH Nagahara","year":"2011","unstructured":"Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10(3):209\u2013219","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"8316_CR71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nn.2136","volume":"11","author":"A Pascual","year":"2008","unstructured":"Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, G\u00f3mez-D\u00edaz R, L\u00f3pez-Barneo J (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11(7):755\u2013761","journal-title":"Nat Neurosci"},{"issue":"2","key":"8316_CR72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1016-8478(23)13040-8","volume":"17","author":"J-S Choi","year":"2004","unstructured":"Choi J-S, Kim SY, Park H-J, Cha J-H, Choi Y-S, Chung J-W, Chun M-H, Lee M-Y (2004) Differential regulation of ciliary neurotrophic factor and its receptor in the rat hippocampus in response to kainic acid-induced excitotoxicity. Mol Cells 17(2):292\u2013296","journal-title":"Mol Cells"},{"issue":"5","key":"8316_CR73","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1460-9568.2006.04642.x","volume":"23","author":"NC Royo","year":"2006","unstructured":"Royo NC, Conte V, Saatman KE, Shimizu S, Belfield CM, Soltesz KM, Davis JE, Fujimoto ST, McIntosh TK (2006) Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4\/5 in pyramidal cell neuroprotection. Eur J Neurosci 23(5):1089\u20131102","journal-title":"Eur J Neurosci"},{"key":"8316_CR74","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0079-6123(09)17514-3","volume":"175","author":"S Ramaswamy","year":"2009","unstructured":"Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson\u2019s disease. Prog Brain Res 175:201\u2013216","journal-title":"Prog Brain Res"},{"issue":"6","key":"8316_CR75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","volume":"5","author":"C Zuccato","year":"2009","unstructured":"Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5(6):311\u2013322","journal-title":"Nat Rev Neurol"},{"issue":"5529","key":"8316_CR76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293(5529):493\u2013498","journal-title":"Science"},{"issue":"2","key":"8316_CR77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","volume":"52","author":"C Zuccato","year":"2005","unstructured":"Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E (2005) Progressive loss of BDNF in a mouse model of Huntington\u2019s disease and rescue by BDNF delivery. Pharmacol Res 52(2):133\u2013139","journal-title":"Pharmacol Res"},{"issue":"1","key":"8316_CR78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127\u2013138","journal-title":"Cell"},{"issue":"1","key":"8316_CR79","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35(1):76\u201383","journal-title":"Nat Genet"},{"issue":"35","key":"8316_CR80","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","volume":"24","author":"JM Canals","year":"2004","unstructured":"Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Mart\u00edn-Iba\u00f1ez R, Mu\u00f1oz MT, Mengod G, Ernfors P, Alberch J (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease. J Neurosci 24(35):7727\u20137739","journal-title":"J Neurosci"},{"issue":"5","key":"8316_CR81","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1471-4159.2005.03047.x","volume":"93","author":"JR Pineda","year":"2005","unstructured":"Pineda JR, Canals JM, Bosch M, Adell A, Mengod G, Artigas F, Ernfors P, Alberch J (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington\u2019s disease. J Neurochem 93(5):1057\u20131068","journal-title":"J Neurochem"},{"issue":"4","key":"8316_CR82","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.neuroscience.2008.11.024","volume":"158","author":"A Giralt","year":"2009","unstructured":"Giralt A, Rodrigo T, Mart\u00edn ED, Gonzalez JR, Mil\u00e0 M, Ce\u00f1a V, Dierssen M, Canals JM, Alberch J (2009) Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 158(4):1234\u20131250","journal-title":"Neuroscience"},{"issue":"18","key":"8316_CR83","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1089\/10430349950016393","volume":"10","author":"AP Bemelmans","year":"1999","unstructured":"Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington\u2019s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10(18):2987\u20132997","journal-title":"Hum Gene Ther"},{"issue":"3","key":"8316_CR84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/nbdi.2001.0388","volume":"8","author":"LP Almeida de","year":"2001","unstructured":"de Almeida LP, Zala D, Aebischer P, D\u00e9glon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington\u2019s disease. Neurobiol Dis 8(3):433\u2013446","journal-title":"Neurobiol Dis"},{"issue":"5","key":"8316_CR85","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1046\/j.1471-4159.2000.0752190.x","volume":"75","author":"E P\u00e9rez-Navarro","year":"2000","unstructured":"P\u00e9rez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E (2000) Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4\/5 prevent the death of striatal projection neurons in a rodent model of Huntington\u2019s disease. J Neurochem 75(5):2190\u20132199","journal-title":"J Neurochem"},{"issue":"2","key":"8316_CR86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","volume":"105","author":"K Gharami","year":"2008","unstructured":"Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington\u2019s disease phenotypes in mice. J Neurochem 105(2):369\u2013379","journal-title":"J Neurochem"},{"issue":"44","key":"8316_CR87","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci 30(44):14708\u201314718","journal-title":"J Neurosci"},{"issue":"10","key":"8316_CR88","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1172\/JCI31778","volume":"117","author":"S-R Cho","year":"2007","unstructured":"Cho S-R, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA (2007) Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 117(10):2889\u20132902","journal-title":"J Clin Invest"},{"issue":"24","key":"8316_CR89","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1073\/pnas.0508875103","volume":"103","author":"JL McBride","year":"2006","unstructured":"McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 103(24):9345\u20139350","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8316_CR90","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nbd.2008.12.005","volume":"34","author":"S Ramaswamy","year":"2009","unstructured":"Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis 34(1):40\u201350","journal-title":"Neurobiol Dis"},{"issue":"2","key":"8316_CR91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbr.2010.05.023","volume":"214","author":"ND Dey","year":"2010","unstructured":"Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington\u2019s disease. Behav Brain Res 214(2):193\u2013200","journal-title":"Behav Brain Res"},{"issue":"50","key":"8316_CR92","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1073\/pnas.0506375102","volume":"102","author":"K Jin","year":"2005","unstructured":"Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, Logvinova A, Ross CA, Greenberg DA, Ellerby LM (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington\u2019s disease. Proc Natl Acad Sci USA 102(50):18189\u201318194","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"8316_CR93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.expneurol.2003.09.002","volume":"185","author":"D Zala","year":"2004","unstructured":"Zala D, Bensadoun J-C, Pereira de Almeida L, Leavitt BR, Gutekunst C-A, Aebischer P, Hayden MR, D\u00e9glon N (2004) Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington\u2019s disease transgenic mice. Exp Neurol 185(1):26\u201335","journal-title":"Exp Neurol"},{"issue":"8","key":"8316_CR94","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jnr.21636","volume":"86","author":"EM Denovan-Wright","year":"2008","unstructured":"Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ (2008) Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6\/1 mice. J Neurosci Res 86(8):1748\u20131757","journal-title":"J Neurosci Res"},{"issue":"4","key":"8316_CR95","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","volume":"55","author":"W Duan","year":"2004","unstructured":"Duan W, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP (2004) Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55(4):590\u2013594","journal-title":"Ann Neurol"},{"issue":"3","key":"8316_CR96","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","volume":"30","author":"W Duan","year":"2008","unstructured":"Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL, Wong J, Ross CA (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington\u2019s disease. Neurobiol Dis 30(3):312\u2013322","journal-title":"Neurobiol Dis"},{"issue":"8","key":"8316_CR97","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","volume":"22","author":"HE Grote","year":"2005","unstructured":"Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ (2005) Cognitive disorders and neurogenesis deficits in Huntington\u2019s disease mice are rescued by fluoxetine. Eur J Neurosci 22(8):2081\u20132088","journal-title":"Eur J Neurosci"},{"issue":"3","key":"8316_CR98","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.neuroimage.2011.02.022","volume":"56","author":"Y Cheng","year":"2011","unstructured":"Cheng Y, Peng Q, Hou Z, Aggarwal M, Zhang J, Mori S, Ross CA, Duan W (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington\u2019s disease mouse model. NeuroImage 56(3):1027\u20131034","journal-title":"NeuroImage"},{"issue":"1","key":"8316_CR99","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","volume":"210","author":"Q Peng","year":"2008","unstructured":"Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model. Exp Neurol 210(1):154\u2013163","journal-title":"Exp Neurol"},{"issue":"1","key":"8316_CR100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.npp.1301571","volume":"33","author":"K Martinowich","year":"2008","unstructured":"Martinowich K, Lu B (2008) Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73\u201383","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"8316_CR101","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1073\/pnas.0811228106","volume":"106","author":"DA Simmons","year":"2009","unstructured":"Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G (2009) Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington\u2019s disease knockin mice. Proc Natl Acad Sci U S A 106(12):4906\u20134911","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8316_CR102","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.nbd.2010.10.015","volume":"41","author":"DA Simmons","year":"2011","unstructured":"Simmons DA, Mehta RA, Lauterborn JC, Gall CM, Lynch G (2011) Brief ampakine treatments slow the progression of Huntington\u2019s disease phenotypes in R6\/2 mice. Neurobiol Dis 41(2):436\u2013444","journal-title":"Neurobiol Dis"},{"issue":"1","key":"8316_CR103","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mcn.2008.04.007","volume":"39","author":"BL Apostol","year":"2008","unstructured":"Apostol BL, Simmons DA, Zuccato C et al (2008) CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6\/2 mice. Mol Cell Neurosci 39(1):8\u201320","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"8316_CR104","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.nbd.2008.02.010","volume":"30","author":"Z DeMarch","year":"2008","unstructured":"DeMarch Z, Giamp\u00e0 C, Patassini S, Bernardi G, Fusco FR (2008) Beneficial effects of rolipram in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 30(3):375\u2013387","journal-title":"Neurobiol Dis"},{"issue":"10","key":"8316_CR105","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","volume":"5","author":"C Giamp\u00e0","year":"2010","unstructured":"Giamp\u00e0 C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS One 5(10):e13417","journal-title":"PLoS One"},{"issue":"4","key":"8316_CR106","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.neuroscience.2009.07.048","volume":"163","author":"KJ Cho","year":"2009","unstructured":"Cho KJ, Lee BI, Cheon SY, Kim HW, Kim HJ, Kim GW (2009) Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Neuroscience 163(4):1128\u20131134","journal-title":"Neuroscience"},{"issue":"3","key":"8316_CR107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2006.08.011","volume":"24","author":"JA Saydoff","year":"2006","unstructured":"Saydoff JA, Garcia RAG, Browne SE et al (2006) Oral uridine pro-drug PN401 is neuroprotective in the R6\/2 and N171-82Q mouse models of Huntington\u2019s disease. Neurobiol Dis 24(3):455\u2013465","journal-title":"Neurobiol Dis"},{"issue":"1","key":"8316_CR108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","volume":"41","author":"T Hathorn","year":"2011","unstructured":"Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1\u03b1 and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis 41(1):43\u201350","journal-title":"Neurobiol Dis"},{"issue":"20","key":"8316_CR109","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddq322","volume":"19","author":"M-C Chiang","year":"2010","unstructured":"Chiang M-C, Chen C-M, Lee M-R et al (2010) Modulation of energy deficiency in Huntington\u2019s disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 19(20):4043\u20134058","journal-title":"Hum Mol Genet"},{"issue":"5","key":"8316_CR110","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI27607","volume":"116","author":"M Borrell-Pag\u00e8s","year":"2006","unstructured":"Borrell-Pag\u00e8s M, Canals JM, Cordeli\u00e8res FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116(5):1410\u20131424","journal-title":"J Clin Invest"},{"issue":"5","key":"8316_CR111","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1073\/pnas.0536856100","volume":"100","author":"W Duan","year":"2003","unstructured":"Duan W, Guo Z, Jiang H, Ware M, Li X-J, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100(5):2911\u20132916","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8316_CR112","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.expneurol.2005.11.010","volume":"198","author":"E Fumagalli","year":"2006","unstructured":"Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol 198(1):114\u2013128","journal-title":"Exp Neurol"},{"issue":"9","key":"8316_CR113","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.npp.1301615","volume":"33","author":"F Meisner","year":"2008","unstructured":"Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, ter Meulen V, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 33(9):2228\u20132236","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"8316_CR114","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.neuron.2008.09.002","volume":"59","author":"PL Greer","year":"2008","unstructured":"Greer PL, Greenberg ME (2008) From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 59(6):846\u2013860","journal-title":"Neuron"},{"issue":"5\u20136","key":"8316_CR115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol 81(5\u20136):294\u2013330","journal-title":"Prog Neurobiol"},{"issue":"3","key":"8316_CR116","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/35044558","volume":"1","author":"H Praag van","year":"2000","unstructured":"van Praag H, Kempermann G, Gage FH (2000) Neural consequences of environmental enrichment. Nat Rev Neurosci 1(3):191\u2013198","journal-title":"Nat Rev Neurosci"},{"issue":"6779","key":"8316_CR117","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","volume":"404","author":"A Dellen van","year":"2000","unstructured":"van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington\u2019s in mice. Nature 404(6779):721\u2013722","journal-title":"Nature"},{"issue":"5","key":"8316_CR118","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/1531-8257(200009)15:5<925::AID-MDS1025>3.0.CO;2-Z","volume":"15","author":"RJ Carter","year":"2000","unstructured":"Carter RJ, Hunt MJ, Morton AJ (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington\u2019s disease gene. Mov Disord 15(5):925\u2013937","journal-title":"Mov Disord"},{"issue":"2","key":"8316_CR119","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10094","volume":"51","author":"E Hockly","year":"2002","unstructured":"Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP (2002) Environmental enrichment slows disease progression in R6\/2 Huntington\u2019s disease mice. Ann Neurol 51(2):235\u2013242","journal-title":"Ann Neurol"},{"issue":"1","key":"8316_CR120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","volume":"123","author":"M Glass","year":"2004","unstructured":"Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RLM (2004) Delayed onset of Huntington\u2019s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123(1):207\u2013212","journal-title":"Neuroscience"},{"issue":"9","key":"8316_CR121","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","volume":"24","author":"TL Spires","year":"2004","unstructured":"Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington\u2019s disease, indicating a possible disease mechanism. J Neurosci 24(9):2270\u20132276","journal-title":"J Neurosci"},{"issue":"7","key":"8316_CR122","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1460-9568.2006.04715.x","volume":"23","author":"SE Lazic","year":"2006","unstructured":"Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, Phillips W, Barker RA (2006) Neurogenesis in the R6\/1 transgenic mouse model of Huntington\u2019s disease: effects of environmental enrichment. Eur J Neurosci 23(7):1829\u20131838","journal-title":"Eur J Neurosci"},{"issue":"2","key":"8316_CR123","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neuroscience.2006.04.013","volume":"141","author":"TYC Pang","year":"2006","unstructured":"Pang TYC, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington\u2019s disease transgenic mice. Neuroscience 141(2):569\u2013584","journal-title":"Neuroscience"},{"issue":"3","key":"8316_CR124","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.nbd.2007.11.006","volume":"29","author":"J Nithianantharajah","year":"2008","unstructured":"Nithianantharajah J, Barkus C, Murphy M, Hannan AJ (2008) Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington\u2019s disease transgenic mice. Neurobiol Dis 29(3):490\u2013504","journal-title":"Neurobiol Dis"},{"key":"8316_CR125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2202-9-34","volume":"9","author":"A Dellen van","year":"2008","unstructured":"van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ (2008) Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington\u2019s disease. BMC Neurosci 9:34","journal-title":"BMC Neurosci"},{"issue":"8","key":"8316_CR126","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/NEN.0b013e3181ea167f","volume":"69","author":"CL Benn","year":"2010","unstructured":"Benn CL, Luthi-Carter R, Kuhn A et al (2010) Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 69(8):817\u2013827","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"8316_CR127","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.nbd.2011.02.005","volume":"42","author":"NI Wood","year":"2011","unstructured":"Wood NI, Glynn D, Morton AJ (2011) \u201cBrain training\u201d improves cognitive performance and survival in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis 42(3):427\u2013437","journal-title":"Neurobiol Dis"},{"issue":"5","key":"8316_CR128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hipo.20658","volume":"20","author":"MS Zajac","year":"2010","unstructured":"Zajac MS, Pang TYC, Wong N, Weinrich B, Leang LSK, Craig JM, Saffery R, Hannan AJ (2010) Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington\u2019s disease mice. Hippocampus 20(5):621\u2013636","journal-title":"Hippocampus"},{"issue":"2","key":"8316_CR129","doi-asserted-by":"crossref","first-page":"e9077","DOI":"10.1371\/journal.pone.0009077","volume":"5","author":"NI Wood","year":"2010","unstructured":"Wood NI, Carta V, Milde S et al (2010) Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington\u2019s disease. PLoS One 5(2):e9077","journal-title":"PLoS One"},{"issue":"1\u20132","key":"8316_CR130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0006-8993(96)00273-9","volume":"726","author":"SA Neeper","year":"1996","unstructured":"Neeper SA, G\u00f3mez-Pinilla F, Choi J, Cotman CW (1996) Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 726(1\u20132):49\u201356","journal-title":"Brain Res"},{"issue":"23","key":"8316_CR131","doi-asserted-by":"crossref","first-page":"12880","DOI":"10.1073\/pnas.97.23.12880","volume":"97","author":"C Rampon","year":"2000","unstructured":"Rampon C, Jiang CH, Dong H, Tang YP, Lockhart DJ, Schultz PG, Tsien JZ, Hu Y (2000) Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci USA 97(23):12880\u201312884","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"8316_CR132","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1046\/j.1460-9568.2003.02647.x","volume":"17","author":"J Brown","year":"2003","unstructured":"Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage FH, Kuhn HG (2003) Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 17(10):2042\u20132046","journal-title":"Eur J Neurosci"},{"key":"8316_CR133","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2007.04.039","volume":"1155","author":"Z Kohl","year":"2007","unstructured":"Kohl Z, Kandasamy M, Winner B, Aigner R, Gross C, Couillard-Despres S, Bogdahn U, Aigner L, Winkler J (2007) Physical activity fails to rescue hippocampal neurogenesis deficits in the R6\/2 mouse model of Huntington\u2019s disease. Brain Res 1155:24\u201333","journal-title":"Brain Res"},{"issue":"2","key":"8316_CR134","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","volume":"90","author":"R Schwarcz","year":"2010","unstructured":"Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington\u2019s disease. Prog Neurobiol 90(2):230\u2013245","journal-title":"Prog Neurobiol"},{"issue":"2","key":"8316_CR135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/exnr.1997.6724","volume":"149","author":"G Figueredo-Cardenas","year":"1998","unstructured":"Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 149(2):356\u2013372","journal-title":"Exp Neurol"},{"issue":"12A","key":"8316_CR136","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0028-3908(83)90221-6","volume":"22","author":"AC Foster","year":"1983","unstructured":"Foster AC, Collins JF, Schwarcz R (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22(12A):1331\u20131342","journal-title":"Neuropharmacology"},{"issue":"7","key":"8316_CR137","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.5473-08.2009","volume":"29","author":"RK Graham","year":"2009","unstructured":"Graham RK, Pouladi MA, Joshi P et al (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29(7):2193\u20132204","journal-title":"J Neurosci"},{"issue":"6","key":"8316_CR138","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","volume":"33","author":"MM Zeron","year":"2002","unstructured":"Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington\u2019s disease. Neuron 33(6):849\u2013860","journal-title":"Neuron"},{"issue":"4","key":"8316_CR139","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F","volume":"58","author":"MS Levine","year":"1999","unstructured":"Levine MS, Klapstein GJ, Koppel A et al (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knock-in mouse models of Huntington\u2019s disease. J Neurosci Res 58(4):515\u2013532","journal-title":"J Neurosci Res"},{"issue":"3","key":"8316_CR140","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1042\/AN20100007","volume":"2","author":"DM Cummings","year":"2010","unstructured":"Cummings DM, Cepeda C, Levine MS (2010) Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington\u2019s disease. ASN Neuro 2(3):e00036","journal-title":"ASN Neuro"},{"issue":"6","key":"8316_CR141","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1152\/jn.2001.86.6.2667","volume":"86","author":"GJ Klapstein","year":"2001","unstructured":"Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6\/2 Huntington\u2019s disease transgenic mice. J Neurophysiol 86(6):2667\u20132677","journal-title":"J Neurophysiol"},{"issue":"3","key":"8316_CR142","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jnr.20651","volume":"82","author":"AJ Starling","year":"2005","unstructured":"Starling AJ, Andr\u00e9 VM, Cepeda C, de Lima M, Chandler SH, Levine MS (2005) Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6\/2 mouse model of Huntington\u2019s disease. J Neurosci Res 82(3):377\u2013386","journal-title":"J Neurosci Res"},{"issue":"4","key":"8316_CR143","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1152\/jn.01118.2005","volume":"95","author":"VM Andr\u00e9","year":"2006","unstructured":"Andr\u00e9 VM, Cepeda C, Venegas A, Gomez Y, Levine MS (2006) Altered cortical glutamate receptor function in the R6\/2 model of Huntington\u2019s disease. J Neurophysiol 95(4):2108\u20132119","journal-title":"J Neurophysiol"},{"issue":"33","key":"8316_CR144","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1523\/JNEUROSCI.1592-09.2009","volume":"29","author":"DM Cummings","year":"2009","unstructured":"Cummings DM, Andr\u00e9 VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, Levine MS (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington\u2019s disease. J Neurosci 29(33):10371\u201310386","journal-title":"J Neurosci"},{"issue":"5\u20136","key":"8316_CR145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pneurobio.2006.11.001","volume":"81","author":"C Cepeda","year":"2007","unstructured":"Cepeda C, Wu N, Andr\u00e9 VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington\u2019s disease. Prog Neurobiol 81(5\u20136):253\u2013271","journal-title":"Prog Neurobiol"},{"issue":"1","key":"8316_CR146","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","volume":"23","author":"P Guidetti","year":"2006","unstructured":"Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23(1):190\u2013197","journal-title":"Neurobiol Dis"},{"issue":"5\u20136","key":"8316_CR147","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2006.11.003","volume":"81","author":"MMY Fan","year":"2007","unstructured":"Fan MMY, Raymond LA (2007) N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington\u2019s disease. Prog Neurobiol 81(5\u20136):272\u2013293","journal-title":"Prog Neurobiol"},{"issue":"12","key":"8316_CR148","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1096\/fj.08-107268","volume":"22","author":"F L\u00e9veill\u00e9","year":"2008","unstructured":"L\u00e9veill\u00e9 F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A (2008) Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 22(12):4258\u20134271","journal-title":"FASEB J"},{"issue":"12","key":"8316_CR149","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","volume":"15","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Pouladi MA, Talantova M et al (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15(12):1407\u20131413","journal-title":"Nat Med"},{"issue":"2","key":"8316_CR150","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","volume":"65","author":"AJ Milnerwood","year":"2010","unstructured":"Milnerwood AJ, Gladding CM, Pouladi MA et al (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice. Neuron 65(2):178\u2013190","journal-title":"Neuron"},{"issue":"24","key":"8316_CR151","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.1073\/pnas.0903546106","volume":"106","author":"RI Stanika","year":"2009","unstructured":"Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB (2009) Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A 106(24):9854\u20139859","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8316_CR152","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.expneurol.2010.07.015","volume":"225","author":"SJ Tallaksen-Greene","year":"2010","unstructured":"Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL (2010) Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6\/2 model of Huntington disease. Exp Neurol 225(2):402\u2013407","journal-title":"Exp Neurol"},{"issue":"3","key":"8316_CR153","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","volume":"315","author":"G Schilling","year":"2001","unstructured":"Schilling G, Coonfield ML, Ross CA, Borchelt DR (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model. Neurosci Lett 315(3):149\u2013153","journal-title":"Neurosci Lett"},{"issue":"5","key":"8316_CR154","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","volume":"22","author":"RJ Ferrante","year":"2002","unstructured":"Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease. J Neurosci 22(5):1592\u20131599","journal-title":"J Neurosci"},{"issue":"1","key":"8316_CR155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2004.05.008","volume":"17","author":"M Gianfriddo","year":"2004","unstructured":"Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis 17(1):77\u201388","journal-title":"Neurobiol Dis"},{"issue":"2","key":"8316_CR156","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nbd.2007.07.009","volume":"28","author":"MR Domenici","year":"2007","unstructured":"Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 28(2):197\u2013205","journal-title":"Neurobiol Dis"},{"issue":"16","key":"8316_CR157","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1093\/hmg\/ddp230","volume":"18","author":"M-C Chiang","year":"2009","unstructured":"Chiang M-C, Chen H-M, Lai H-L, Chen H-W, Chou S-Y, Chen C-M, Tsai F-J, Chern Y (2009) The A2A adenosine receptor rescues the urea cycle deficiency of Huntington\u2019s disease by enhancing the activity of the ubiquitin-proteasome system. Hum Mol Genet 18(16):2929\u20132942","journal-title":"Hum Mol Genet"},{"issue":"6","key":"8316_CR158","doi-asserted-by":"crossref","first-page":"e20934","DOI":"10.1371\/journal.pone.0020934","volume":"6","author":"N-K Huang","year":"2011","unstructured":"Huang N-K, Lin J-H, Lin J-T et al (2011) A new drug design targeting the adenosinergic system for Huntington\u2019s disease. PLoS One 6(6):e20934","journal-title":"PLoS One"},{"issue":"2","key":"8316_CR159","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1471-4159.2005.03029.x","volume":"93","author":"S-Y Chou","year":"2005","unstructured":"Chou S-Y, Lee Y-C, Chen H-M et al (2005) CGS21680 attenuates symptoms of Huntington\u2019s disease in a transgenic mouse model. J Neurochem 93(2):310\u2013320","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"8316_CR160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","volume":"1019","author":"J Schiefer","year":"2004","unstructured":"Schiefer J, Spr\u00fcnken A, Puls C, L\u00fcesse H-G, Milkereit A, Milkereit E, Johann V, Kosinski CM (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease. Brain Res 1019(1\u20132):246\u2013254","journal-title":"Brain Res"},{"issue":"1","key":"8316_CR161","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","volume":"47","author":"A Reiner","year":"2012","unstructured":"Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP (2012) The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice. Neurobiol Dis 47(1):75\u201391","journal-title":"Neurobiol Dis"},{"issue":"1","key":"8316_CR162","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington\u2019s disease phenotype in the R6\/2 mouse. Neuroscience 153(1):329\u2013337","journal-title":"Neuroscience"},{"key":"8316_CR163","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1423-0127-17-62","volume":"17","author":"Y Sari","year":"2010","unstructured":"Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV (2010) Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6\/2 model of Huntington\u2019s disease. J Biomed Sci 17:62","journal-title":"J Biomed Sci"},{"issue":"10","key":"8316_CR164","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1523\/JNEUROSCI.20-10-03596.2000","volume":"20","author":"M Figiel","year":"2000","unstructured":"Figiel M, Engele J (2000) Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism. J Neurosci 20(10):3596\u20133605","journal-title":"J Neurosci"},{"issue":"1","key":"8316_CR165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-4886(03)00134-1","volume":"183","author":"M Figiel","year":"2003","unstructured":"Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J (2003) Regulation of glial glutamate transporter expression by growth factors. Exp Neurol 183(1):124\u2013135","journal-title":"Exp Neurol"},{"issue":"30","key":"8316_CR166","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","volume":"27","author":"T-S Tang","year":"2007","unstructured":"Tang T-S, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease. J Neurosci 27(30):7899\u20137910","journal-title":"J Neurosci"},{"key":"8316_CR167","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-5-18","volume":"5","author":"H Wang","year":"2010","unstructured":"Wang H, Chen X, Li Y, Tang T-S, Bezprozvanny I (2010) Tetrabenazine is neuroprotective in Huntington\u2019s disease mice. Mol Neurodegener 5:18","journal-title":"Mol Neurodegener"},{"issue":"3","key":"8316_CR168","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","volume":"30","author":"N Masuda","year":"2008","unstructured":"Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington\u2019s disease. Neurobiol Dis 30(3):293\u2013302","journal-title":"Neurobiol Dis"},{"issue":"1","key":"8316_CR169","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","volume":"170","author":"MJ Dowie","year":"2010","unstructured":"Dowie MJ, Howard ML, Nicholson LFB, Faull RLM, Hannan AJ, Glass M (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice. Neuroscience 170(1):324\u2013336","journal-title":"Neuroscience"},{"issue":"6","key":"8316_CR170","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/187152710793237430","volume":"9","author":"MA Thevandavakkam","year":"2010","unstructured":"Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F (2010) Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington\u2019s disease. CNS Neurol Disord Drug Targets 9(6):791\u2013800","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"3","key":"8316_CR171","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17(3):455\u2013461","journal-title":"Neurobiol Dis"},{"issue":"6","key":"8316_CR172","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","volume":"113","author":"KV Sathyasaikumar","year":"2010","unstructured":"Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R (2010) Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington\u2019s disease. J Neurochem 113(6):1416\u20131425","journal-title":"J Neurochem"},{"issue":"11","key":"8316_CR173","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"S Campesan","year":"2011","unstructured":"Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol 21(11):961\u2013966","journal-title":"Curr Biol"},{"issue":"6","key":"8316_CR174","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang S-Y, Sathyasaikumar KV et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145(6):863\u2013874","journal-title":"Cell"},{"issue":"3","key":"8316_CR175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol 39(3):385\u2013389","journal-title":"Ann Neurol"},{"issue":"5","key":"8316_CR176","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","volume":"41","author":"SE Browne","year":"1997","unstructured":"Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: selective vulnerability of the basal ganglia. Ann Neurol 41(5):646\u2013653","journal-title":"Ann Neurol"},{"key":"8316_CR177","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1749-6632.1999.tb07856.x","volume":"893","author":"A Panov","year":"1999","unstructured":"Panov A, Obertone T, Bennett-Desmelik J, Greenamyre JT (1999) Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington\u2019s or Alzheimer\u2019s disease. Ann N Y Acad Sci 893:365\u2013368","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"8316_CR178","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731\u2013736","journal-title":"Nat Neurosci"},{"issue":"35","key":"8316_CR179","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.1074\/jbc.M504749200","volume":"280","author":"T Milakovic","year":"2005","unstructured":"Milakovic T, Johnson GVW (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280(35):30773\u201330782","journal-title":"J Biol Chem"},{"issue":"1","key":"8316_CR180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1):59\u201369","journal-title":"Cell"},{"issue":"5","key":"8316_CR181","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab 4(5):349\u2013362","journal-title":"Cell Metab"},{"issue":"11","key":"8316_CR182","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbabio.2009.06.009","volume":"1787","author":"JJ Lemasters","year":"2009","unstructured":"Lemasters JJ, Theruvath TP, Zhong Z, Nieminen A-L (2009) Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 1787(11):1395\u20131401","journal-title":"Biochim Biophys Acta"},{"issue":"14","key":"8316_CR183","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","volume":"13","author":"YS Choo","year":"2004","unstructured":"Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13(14):1407\u20131420","journal-title":"Hum Mol Genet"},{"issue":"9\u201310","key":"8316_CR184","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/00001756-199707070-00031","volume":"8","author":"J Block-Galarza","year":"1997","unstructured":"Block-Galarza J, Chase KO, Sapp E, Vaughn KT, Vallee RB, DiFiglia M, Aronin N (1997) Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport 8(9\u201310):2247\u20132251","journal-title":"Neuroreport"},{"issue":"11","key":"8316_CR185","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1523\/JNEUROSCI.0106-08.2008","volume":"28","author":"AL Orr","year":"2008","unstructured":"Orr AL, Li S, Wang C-E, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li X-J (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28(11):2783\u20132792","journal-title":"J Neurosci"},{"issue":"2","key":"8316_CR186","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.nbd.2005.12.007","volume":"22","author":"DTW Chang","year":"2006","unstructured":"Chang DTW, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22(2):388\u2013400","journal-title":"Neurobiol Dis"},{"issue":"6","key":"8316_CR187","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","volume":"1762","author":"KM Smith","year":"2006","unstructured":"Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington\u2019s disease mice. Biochim Biophys Acta 1762(6):616\u2013626","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"8316_CR188","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","volume":"1762","author":"EC Stack","year":"2006","unstructured":"Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ (2006) Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice. Biochim Biophys Acta 1762(3):373\u2013380","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"8316_CR189","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","volume":"109","author":"L Yang","year":"2009","unstructured":"Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases. J Neurochem 109(5):1427\u20131439","journal-title":"J Neurochem"},{"issue":"3","key":"8316_CR190","doi-asserted-by":"crossref","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","volume":"5","author":"LB Menalled","year":"2010","unstructured":"Menalled LB, Patry M, Ragland N et al (2010) Comprehensive behavioral testing in the R6\/2 mouse model of Huntington\u2019s disease shows no benefit from CoQ10 or minocycline. PLoS One 5(3):e9793","journal-title":"PLoS One"},{"issue":"5","key":"8316_CR191","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10715760600617843","volume":"40","author":"HN Bhagavan","year":"2006","unstructured":"Bhagavan HN, Chopra RK (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40(5):445\u2013453","journal-title":"Free Radic Res"},{"issue":"4","key":"8316_CR192","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/13543781003727495","volume":"19","author":"JM Villalba","year":"2010","unstructured":"Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ (2010) Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19(4):535\u2013554","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"8316_CR193","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.1085","volume":"50","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Ferrante RJ, Huang HM et al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington\u2019s disease. Ann Neurol 50(1):112\u2013117","journal-title":"Ann Neurol"},{"issue":"15","key":"8316_CR194","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1097\/00001756-200110290-00044","volume":"12","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF (2001) Lipoic acid improves survival in transgenic mouse models of Huntington\u2019s disease. Neuroreport 12(15):3371\u20133373","journal-title":"Neuroreport"},{"issue":"6","key":"8316_CR195","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","volume":"85","author":"A Dedeoglu","year":"2003","unstructured":"Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice. J Neurochem 85(6):1359\u20131367","journal-title":"J Neurochem"},{"issue":"3","key":"8316_CR196","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","volume":"8","author":"OA Andreassen","year":"2001","unstructured":"Andreassen OA, Dedeoglu A, Ferrante RJ et al (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease. Neurobiol Dis 8(3):479\u2013491","journal-title":"Neurobiol Dis"},{"issue":"12","key":"8316_CR197","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","volume":"20","author":"RJ Ferrante","year":"2000","unstructured":"Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease. J Neurosci 20(12):4389\u20134397","journal-title":"J Neurosci"},{"issue":"5","key":"8316_CR198","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.physbeh.2011.04.001","volume":"103","author":"DN Ruskin","year":"2011","unstructured":"Ruskin DN, Ross JL, Kawamura M Jr, Ruiz TL, Geiger JD, Masino SA (2011) A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6\/2 1\u00a0J mouse model of Huntington\u2019s disease. Physiol Behav 103(5):501\u2013507","journal-title":"Physiol Behav"},{"issue":"1","key":"8316_CR199","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biopha.2003.11.004","volume":"58","author":"J Emerit","year":"2004","unstructured":"Emerit J, Edeas M, Bricaire F (2004) Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58(1):39\u201346","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"8316_CR200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-010-0788-5","volume":"121","author":"J Lee","year":"2011","unstructured":"Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H (2011) Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington\u2019s disease mice. Acta Neuropathol 121(4):487\u2013498","journal-title":"Acta Neuropathol"},{"issue":"16","key":"8316_CR201","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","volume":"99","author":"CD Keene","year":"2002","unstructured":"Keene CD, Rodrigues CMP, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 99(16):10671\u201310676","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8316_CR202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1471-4159.2003.t01-1-01868.x","volume":"86","author":"P Klivenyi","year":"2003","unstructured":"Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier P-E, Beal MF (2003) Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington\u2019s disease. J Neurochem 86(1):267\u2013272","journal-title":"J Neurochem"},{"issue":"9","key":"8316_CR203","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/00001756-200307010-00015","volume":"14","author":"GV Rebec","year":"2003","unstructured":"Rebec GV, Barton SJ, Marseilles AM, Collins K (2003) Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14(9):1263\u20131265","journal-title":"Neuroreport"},{"issue":"4","key":"8316_CR204","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.biopha.2009.06.020","volume":"64","author":"E Vamos","year":"2010","unstructured":"Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington\u2019s disease. Biomed Pharmacother 64(4):282\u2013286","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"8316_CR205","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2010.03.017","volume":"49","author":"C Stack","year":"2010","unstructured":"Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington\u2019s disease. Free Radic Biol Med 49(2):147\u2013158","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"8316_CR206","doi-asserted-by":"crossref","first-page":"e16172","DOI":"10.1371\/journal.pone.0016172","volume":"6","author":"G Ellrichmann","year":"2011","unstructured":"Ellrichmann G, Petrasch-Parwez E, Lee D-H, Reick C, Arning L, Saft C, Gold R, Linker RA (2011) Efficacy of fumaric acid esters in the R6\/2 and YAC128 models of Huntington\u2019s disease. PLoS One 6(1):e16172","journal-title":"PLoS One"},{"issue":"16","key":"8316_CR207","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","volume":"18","author":"RK Chaturvedi","year":"2009","unstructured":"Chaturvedi RK, Adhihetty P, Shukla S et al (2009) Impaired PGC-1alpha function in muscle in Huntington\u2019s disease. Hum Mol Genet 18(16):3048\u20133065","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8316_CR208","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol 225(1):74\u201384","journal-title":"Exp Neurol"},{"issue":"1","key":"8316_CR209","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2012","unstructured":"Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR 3rd, Bordone L, Guarente L, Krainc D (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159\u2013165","journal-title":"Nat Med"},{"issue":"1","key":"8316_CR210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2012","unstructured":"Jiang M, Wang J, Fu J et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med 18(1):153\u2013158","journal-title":"Nat Med"},{"issue":"3","key":"8316_CR211","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1460-9568.2007.05663.x","volume":"26","author":"H Wang","year":"2007","unstructured":"Wang H, Guan Y, Wang X et al (2007) Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur J Neurosci 26(3):633\u2013641","journal-title":"Eur J Neurosci"},{"issue":"17","key":"8316_CR212","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1093\/hmg\/ddq247","volume":"19","author":"GM Perry","year":"2010","unstructured":"Perry GM, Tallaksen-Greene S, Kumar A, Heng MY, Kneynsberg A, van Groen T, Detloff PJ, Albin RL, Lesort M (2010) Mitochondrial calcium uptake capacity as a therapeutic target in the R6\/2 mouse model of Huntington\u2019s disease. Hum Mol Genet 19(17):3354\u20133371","journal-title":"Hum Mol Genet"},{"issue":"3","key":"8316_CR213","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0896-6273(00)80716-3","volume":"22","author":"I S\u00e1nchez","year":"1999","unstructured":"S\u00e1nchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22(3):623\u2013633","journal-title":"Neuron"},{"issue":"7","key":"8316_CR214","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"M Chen","year":"2000","unstructured":"Chen M, Ona VO, Li M et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6(7):797\u2013801","journal-title":"Nat Med"},{"issue":"2","key":"8316_CR215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncb735","volume":"4","author":"FG Gervais","year":"2002","unstructured":"Gervais FG, Singaraja R, Xanthoudakis S et al (2002) Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 4(2):95\u2013105","journal-title":"Nat Cell Biol"},{"issue":"4","key":"8316_CR216","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.cdd.4401358","volume":"11","author":"E Hermel","year":"2004","unstructured":"Hermel E, Gafni J, Propp SS et al (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington\u2019s disease. Cell Death Differ 11(4):424\u2013438","journal-title":"Cell Death Differ"},{"issue":"3","key":"8316_CR217","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1385\/NMM:1:3:183","volume":"1","author":"T Kiechle","year":"2002","unstructured":"Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ (2002) Cytochrome C and caspase-9 expression in Huntington\u2019s disease. Neuromolecular Med 1(3):183\u2013195","journal-title":"Neuromolecular Med"},{"issue":"1","key":"8316_CR218","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nbd.2008.03.010","volume":"31","author":"H Zhang","year":"2008","unstructured":"Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I (2008) Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington\u2019s disease. Neurobiol Dis 31(1):80\u201388","journal-title":"Neurobiol Dis"},{"issue":"2","key":"8316_CR219","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.nbd.2005.07.011","volume":"21","author":"A-H Chou","year":"2006","unstructured":"Chou A-H, Yeh T-H, Kuo Y-L, Kao Y-C, Jou M-J, Hsu C-Y, Tsai S-R, Kakizuka A, Wang H-L (2006) Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol Dis 21(2):333\u2013345","journal-title":"Neurobiol Dis"},{"issue":"4","key":"8316_CR220","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cellsig.2005.05.024","volume":"18","author":"H-L Wang","year":"2006","unstructured":"Wang H-L, Yeh T-H, Chou A-H, Kuo Y-L, Luo L-J, He C-Y, Huang P-C, Li AH (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal 18(4):541\u2013552","journal-title":"Cell Signal"},{"issue":"2","key":"8316_CR221","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuint.2010.11.005","volume":"58","author":"A-H Chou","year":"2011","unstructured":"Chou A-H, Lin A-C, Hong K-Y, Hu S-H, Chen Y-L, Chen J-Y, Wang H-L (2011) p53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochem Int 58(2):145\u2013152","journal-title":"Neurochem Int"},{"issue":"7","key":"8316_CR222","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1523\/JNEUROSCI.4072-08.2009","volume":"29","author":"JE Young","year":"2009","unstructured":"Young JE, Garden GA, Martinez RA et al (2009) Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5\/Hrk. J Neurosci 29(7):1987\u20131997","journal-title":"J Neurosci"},{"issue":"18","key":"8316_CR223","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","volume":"22","author":"CL Wellington","year":"2002","unstructured":"Wellington CL, Ellerby LM, Gutekunst C-A et al (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington\u2019s disease. J Neurosci 22(18):7862\u20137872","journal-title":"J Neurosci"},{"issue":"4","key":"8316_CR224","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1471-4159.2004.02369.x","volume":"89","author":"SJS Berke","year":"2004","unstructured":"Berke SJS, Schmied FAF, Brunt ER, Ellerby LM, Paulson HL (2004) Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89(4):908\u2013918","journal-title":"J Neurochem"},{"issue":"41","key":"8316_CR225","doi-asserted-by":"crossref","first-page":"30150","DOI":"10.1074\/jbc.M705265200","volume":"282","author":"JE Young","year":"2007","unstructured":"Young JE, Gouw L, Propp S et al (2007) Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem 282(41):30150\u201330160","journal-title":"J Biol Chem"},{"issue":"1","key":"8316_CR226","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1471-4159.1999.0720185.x","volume":"72","author":"LM Ellerby","year":"1999","unstructured":"Ellerby LM, Hackam AS, Propp SS et al (1999) Kennedy\u2019s disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 72(1):185\u2013195","journal-title":"J Neurochem"},{"issue":"13","key":"8316_CR227","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.1074\/jbc.274.13.8730","volume":"274","author":"LM Ellerby","year":"1999","unstructured":"Ellerby LM, Andrusiak RL, Wellington CL et al (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 274(13):8730\u20138736","journal-title":"J Biol Chem"},{"issue":"6","key":"8316_CR228","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","volume":"125","author":"RK Graham","year":"2006","unstructured":"Graham RK, Deng Y, Slow EJ et al (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125(6):1179\u20131191","journal-title":"Cell"},{"issue":"14","key":"8316_CR229","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/hmg\/ddr176","volume":"20","author":"ATN Tebbenkamp","year":"2011","unstructured":"Tebbenkamp ATN, Green C, Xu G et al (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum Mol Genet 20(14):2770\u20132782","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8316_CR230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1523\/JNEUROSCI.1305-11.2012","volume":"32","author":"E Waldron-Roby","year":"2012","unstructured":"Waldron-Roby E, Ratovitski T, Wang X et al (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32(1):183\u2013193","journal-title":"J Neurosci"},{"issue":"1","key":"8316_CR231","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbadis.2009.09.004","volume":"1802","author":"P Nagley","year":"2010","unstructured":"Nagley P, Higgins GC, Atkin JD, Beart PM (2010) Multifaceted deaths orchestrated by mitochondria in neurones. Biochim Biophys Acta 1802(1):167\u2013185","journal-title":"Biochim Biophys Acta"},{"issue":"6733","key":"8316_CR232","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/20446","volume":"399","author":"VO Ona","year":"1999","unstructured":"Ona VO, Li M, Vonsattel JP et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington\u2019s disease. Nature 399(6733):263\u2013267","journal-title":"Nature"},{"issue":"18","key":"8316_CR233","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.1832501100","volume":"100","author":"X Wang","year":"2003","unstructured":"Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington\u2019s disease. Proc Natl Acad Sci USA 100(18):10483\u201310487","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"8316_CR234","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","volume":"19","author":"E Diguet","year":"2004","unstructured":"Diguet E, Fernagut P-O, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F (2004) Deleterious effects of minocycline in animal models of Parkinson\u2019s disease and Huntington\u2019s disease. Eur J Neurosci 19(12):3266\u20133276","journal-title":"Eur J Neurosci"},{"issue":"1","key":"8316_CR235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1385\/NMM:9:1:47","volume":"9","author":"S Mievis","year":"2007","unstructured":"Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C, Blum D (2007) Lack of minocycline efficiency in genetic models of Huntington\u2019s disease. Neuromolecular Med 9(1):47\u201354","journal-title":"Neuromolecular Med"},{"issue":"6","key":"8316_CR236","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ana.21891","volume":"54","author":"S Hersch","year":"2003","unstructured":"Hersch S, Fink K, Vonsattel JP, Friedlander RM (2003) Minocycline is protective in a mouse model of Huntington\u2019s disease. Ann Neurol 54(6):841, author reply 842\u2013843","journal-title":"Ann Neurol"},{"issue":"6","key":"8316_CR237","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","volume":"19","author":"RM Bonelli","year":"2004","unstructured":"Bonelli RM, H\u00f6dl AK, Hofmann P, Kapfhammer H-P (2004) Neuroprotection in Huntington\u2019s disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19(6):337\u2013342","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"8316_CR238","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas M, Ashizawa T, Jankovic J (2004) Minocycline in Huntington\u2019s disease: a pilot study. Mov Disord 19(6):692\u2013695","journal-title":"Mov Disord"},{"issue":"3","key":"8316_CR239","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/01.WNL.0000133403.30559.FF","volume":"63","author":"Huntington Study Group","year":"2004","unstructured":"Huntington Study Group (2004) Minocycline safety and tolerability in Huntington disease. Neurology 63(3):547\u2013549","journal-title":"Neurology"},{"issue":"12","key":"8316_CR240","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/archneurol.2010.191","volume":"67","author":"JM Plane","year":"2010","unstructured":"Plane JM, Shen Y, Pleasure DE, Deng W (2010) Prospects for minocycline neuroprotection. Arch Neurol 67(12):1442\u20131448","journal-title":"Arch Neurol"},{"issue":"12","key":"8316_CR241","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","volume":"6","author":"PH Gordon","year":"2007","unstructured":"Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6(12):1045\u20131053","journal-title":"Lancet Neurol"},{"issue":"13","key":"8316_CR242","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","volume":"25","author":"Huntington Study Group DOMINO Investigators","year":"2010","unstructured":"Huntington Study Group DOMINO Investigators (2010) A futility study of minocycline in Huntington\u2019s disease. Mov Disord 25(13):2219\u20132224","journal-title":"Mov Disord"},{"issue":"38","key":"8316_CR243","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1523\/JNEUROSCI.1867-08.2008","volume":"28","author":"X Wang","year":"2008","unstructured":"Wang X, Zhu S, Pei Z et al (2008) Inhibitors of cytochrome c release with therapeutic potential for Huntington\u2019s disease. J Neurosci 28(38):9473\u20139485","journal-title":"J Neurosci"},{"issue":"6","key":"8316_CR244","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1096\/fj.08-122275","volume":"23","author":"M D\u00edaz-Hern\u00e1ndez","year":"2009","unstructured":"D\u00edaz-Hern\u00e1ndez M, D\u00edez-Zaera M, S\u00e1nchez-Nogueiro J, G\u00f3mez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, Lucas JJ (2009) Altered P2X7-receptor level and function in mouse models of Huntington\u2019s disease and therapeutic efficacy of antagonist administration. FASEB J 23(6):1893\u20131906","journal-title":"FASEB J"},{"issue":"4","key":"8316_CR245","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00005072-199704000-00013","volume":"56","author":"T Arzberger","year":"1997","unstructured":"Arzberger T, Krampfl K, Leimgruber S, Weindl A (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington\u2019s disease\u2014an in situ hybridization study. J Neuropathol Exp Neurol 56(4):440\u2013454","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"8316_CR246","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0306-4522(95)00595-1","volume":"72","author":"SJ Augood","year":"1996","unstructured":"Augood SJ, Faull RL, Love DR, Emson PC (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington\u2019s disease: a detailed cellular in situ hybridization study. Neuroscience 72(4):1023\u20131036","journal-title":"Neuroscience"},{"issue":"10","key":"8316_CR247","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jnen\/62.10.1006","volume":"62","author":"BO Evert","year":"2003","unstructured":"Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, de Vos RAI, Brunt ERP, Klockgether T, W\u00fcllner U (2003) Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 62(10):1006\u20131018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"8316_CR248","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72101","volume":"3","author":"X Lin","year":"2000","unstructured":"Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3(2):157\u2013163","journal-title":"Nat Neurosci"},{"issue":"17","key":"8316_CR249","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/11.17.1927","volume":"11","author":"R Luthi-Carter","year":"2002","unstructured":"Luthi-Carter R, Strand AD, Hanson SA et al (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington\u2019s disease mouse models reveal context-independent effects. Hum Mol Genet 11(17):1927\u20131937","journal-title":"Hum Mol Genet"},{"issue":"12","key":"8316_CR250","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/hmg\/ddh139","volume":"13","author":"D Helmlinger","year":"2004","unstructured":"Helmlinger D, Hardy S, Sasorith S et al (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13(12):1257\u20131265","journal-title":"Hum Mol Genet"},{"issue":"12","key":"8316_CR251","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1073\/pnas.0400615101","volume":"101","author":"C-C Tsai","year":"2004","unstructured":"Tsai C-C, Kao H-Y, Mitzutani A, Banayo E, Rajan H, McKeown M, Evans RM (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci USA 101(12):4047\u20134052","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"8316_CR252","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1038\/sj.emboj.7600785","volume":"24","author":"A Mizutani","year":"2005","unstructured":"Mizutani A, Wang L, Rajan H, Vig PJS, Alaynick WA, Thaler JP, Tsai C-C (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24(18):3339\u20133351","journal-title":"EMBO J"},{"issue":"5","key":"8316_CR253","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/embor.2011.49","volume":"12","author":"X Tong","year":"2011","unstructured":"Tong X, Gui H, Jin F, Heck BW, Lin P, Ma J, Fondell JD, Tsai C-C (2011) Ataxin-1 and Brother of ataxin-1 are components of the Notch signalling pathway. EMBO Rep 12(5):428\u2013435","journal-title":"EMBO Rep"},{"issue":"47","key":"8316_CR254","doi-asserted-by":"crossref","first-page":"45004","DOI":"10.1074\/jbc.M205259200","volume":"277","author":"F Li","year":"2002","unstructured":"Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277(47):45004\u201345012","journal-title":"J Biol Chem"},{"issue":"44","key":"8316_CR255","doi-asserted-by":"crossref","first-page":"11474","DOI":"10.1523\/JNEUROSCI.2053-06.2006","volume":"26","author":"BO Evert","year":"2006","unstructured":"Evert BO, Araujo J, Vieira-Saecker AM, de Vos RAI, Harendza S, Klockgether T, W\u00fcllner U (2006) Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci 26(44):11474\u201311486","journal-title":"J Neurosci"},{"issue":"1","key":"8316_CR256","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/79139","volume":"26","author":"T Shimohata","year":"2000","unstructured":"Shimohata T, Nakajima T, Yamada M et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26(1):29\u201336","journal-title":"Nat Genet"},{"issue":"5","key":"8316_CR257","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0896-6273(02)00697-9","volume":"34","author":"H Okazawa","year":"2002","unstructured":"Okazawa H, Rich T, Chang A et al (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34(5):701\u2013713","journal-title":"Neuron"},{"issue":"1","key":"8316_CR258","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","volume":"47","author":"B-I Bae","year":"2005","unstructured":"Bae B-I, Xu H, Igarashi S et al (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington\u2019s disease. Neuron 47(1):29\u201341","journal-title":"Neuron"},{"issue":"5","key":"8316_CR259","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","volume":"22","author":"S-H Li","year":"2002","unstructured":"Li S-H, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li X-J (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22(5):1277\u20131287","journal-title":"Mol Cell Biol"},{"issue":"17","key":"8316_CR260","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1523\/JNEUROSCI.5409-05.2006","volume":"26","author":"M Arango","year":"2006","unstructured":"Arango M, Holbert S, Zala D et al (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci 26(17):4649\u20134659","journal-title":"J Neurosci"},{"issue":"3","key":"8316_CR261","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nbd.2008.05.005","volume":"31","author":"PA Desplats","year":"2008","unstructured":"Desplats PA, Lambert JR, Thomas EA (2008) Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington\u2019s disease. Neurobiol Dis 31(3):298\u2013308","journal-title":"Neurobiol Dis"},{"issue":"10","key":"8316_CR262","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","volume":"7","author":"R Butler","year":"2006","unstructured":"Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7(10):784\u2013796","journal-title":"Nat Rev Neurosci"},{"issue":"14","key":"8316_CR263","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/hmg\/9.14.2197","volume":"9","author":"A McCampbell","year":"2000","unstructured":"McCampbell A, Taylor JP, Taye AA et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9(14):2197\u20132202","journal-title":"Hum Mol Genet"},{"issue":"5512","key":"8316_CR264","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","volume":"291","author":"FC Nucifora Jr","year":"2001","unstructured":"Nucifora FC Jr, Sasaki M, Peters MF et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512):2423\u20132428","journal-title":"Science"},{"issue":"1","key":"8316_CR265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddg002","volume":"12","author":"H Jiang","year":"2003","unstructured":"Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB (2003) Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 12(1):1\u201312","journal-title":"Hum Mol Genet"},{"issue":"10","key":"8316_CR266","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ncb859","volume":"4","author":"DL Stenoien","year":"2002","unstructured":"Stenoien DL, Mielke M, Mancini MA (2002) Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol 4(10):806\u2013810","journal-title":"Nat Cell Biol"},{"issue":"11","key":"8316_CR267","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","volume":"16","author":"G Sadri-Vakili","year":"2007","unstructured":"Sadri-Vakili G, Bouzou B, Benn CL et al (2007) Histones associated with downregulated genes are hypo-acetylated in Huntington\u2019s disease models. Hum Mol Genet 16(11):1293\u20131306","journal-title":"Hum Mol Genet"},{"issue":"5","key":"8316_CR268","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1460-9568.2009.06649.x","volume":"29","author":"C Giamp\u00e0","year":"2009","unstructured":"Giamp\u00e0 C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR (2009) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6\/2 mouse model of Huntington\u2019s disease. Eur J Neurosci 29(5):902\u2013910","journal-title":"Eur J Neurosci"},{"issue":"2","key":"8316_CR269","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nbd.2010.10.019","volume":"41","author":"A-H Chou","year":"2011","unstructured":"Chou A-H, Chen S-Y, Yeh T-H, Weng Y-H, Wang H-L (2011) HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 41(2):481\u2013488","journal-title":"Neurobiol Dis"},{"issue":"11","key":"8316_CR270","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/hmg\/ddh131","volume":"13","author":"M Minamiyama","year":"2004","unstructured":"Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13(11):1183\u20131192","journal-title":"Hum Mol Genet"},{"issue":"18","key":"8316_CR271","doi-asserted-by":"crossref","first-page":"12580","DOI":"10.1074\/jbc.M511677200","volume":"281","author":"M Ying","year":"2006","unstructured":"Ying M, Xu R, Wu X, Zhu H, Zhuang Y, Han M, Xu T (2006) Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 281(18):12580\u201312586","journal-title":"J Biol Chem"},{"issue":"1","key":"8316_CR272","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian G, Browne SE, Choi D-K et al (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 280(1):556\u2013563","journal-title":"J Biol Chem"},{"issue":"1","key":"8316_CR273","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","volume":"94","author":"D Z\u00e1dori","year":"2009","unstructured":"Z\u00e1dori D, Geisz A, V\u00e1mos E, V\u00e9csei L, Kliv\u00e9nyi P (2009) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington\u2019s disease. Pharmacol Biochem Behav 94(1):148\u2013153","journal-title":"Pharmacol Biochem Behav"},{"issue":"28","key":"8316_CR274","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","volume":"23","author":"RJ Ferrante","year":"2003","unstructured":"Ferrante RJ, Kubilus JK, Lee J et al (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice. J Neurosci 23(28):9418\u20139427","journal-title":"J Neurosci"},{"issue":"4","key":"8316_CR275","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly E, Richon VM, Woodman B et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease. Proc Natl Acad Sci U S A 100(4):2041\u20132046","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"40","key":"8316_CR276","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","volume":"105","author":"EA Thomas","year":"2008","unstructured":"Thomas EA, Coppola G, Desplats PA et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice. Proc Natl Acad Sci USA 105(40):15564\u201315569","journal-title":"Proc Natl Acad Sci USA"},{"issue":"50","key":"8316_CR277","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","volume":"103","author":"H Ryu","year":"2006","unstructured":"Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ (2006) ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington\u2019s disease. Proc Natl Acad Sci U S A 103(50):19176\u201319181","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"46","key":"8316_CR278","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","volume":"24","author":"RJ Ferrante","year":"2004","unstructured":"Ferrante RJ, Ryu H, Kubilus JK et al (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington\u2019s disease. J Neurosci 24(46):10335\u201310342","journal-title":"J Neurosci"},{"issue":"10","key":"8316_CR279","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","volume":"16","author":"EC Stack","year":"2007","unstructured":"Stack EC, Del Signore SJ, Luthi-Carter R et al (2007) Modulation of nucleosome dynamics in Huntington\u2019s disease. Hum Mol Genet 16(10):1164\u20131175","journal-title":"Hum Mol Genet"},{"issue":"Suppl 9","key":"8316_CR280","first-page":"82","volume":"61","author":"HK Manji","year":"2000","unstructured":"Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9):82\u201396","journal-title":"J Clin Psychiatry"},{"issue":"3 Pt 2","key":"8316_CR281","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1399-5618.2000.20303.x","volume":"2","author":"G Chen","year":"2000","unstructured":"Chen G, Masana MI, Manji HK (2000) Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2(3 Pt 2):217\u2013236","journal-title":"Bipolar Disord"},{"issue":"35","key":"8316_CR282","doi-asserted-by":"crossref","first-page":"33067","DOI":"10.1074\/jbc.M212635200","volume":"278","author":"F Zhang","year":"2003","unstructured":"Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278(35):33067\u201333077","journal-title":"J Biol Chem"},{"issue":"5","key":"8316_CR283","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1371\/journal.pmed.0040182","volume":"4","author":"K Watase","year":"2007","unstructured":"Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa H, Orr HT, Shaw C, Zoghbi HY (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4(5):e182","journal-title":"PLoS Med"},{"issue":"4","key":"8316_CR284","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0361-9230(03)00141-2","volume":"61","author":"NI Wood","year":"2003","unstructured":"Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington\u2019s disease mutation. Brain Res Bull 61(4):375\u2013383","journal-title":"Brain Res Bull"},{"issue":"5 Pt 1","key":"8316_CR285","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","volume":"7","author":"TW Miller","year":"2003","unstructured":"Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572\u2013579","journal-title":"Mol Ther"},{"issue":"3","key":"8316_CR286","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ng1977","volume":"39","author":"AB Bowman","year":"2007","unstructured":"Bowman AB, Lam YC, Jafar-Nejad P, Chen H-K, Richman R, Samaco RC, Fryer JD, Kahle JJ, Orr HT, Zoghbi HY (2007) Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet 39(3):373\u2013379","journal-title":"Nat Genet"},{"issue":"2","key":"8316_CR287","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2004.07.011","volume":"17","author":"F Norflus","year":"2004","unstructured":"Norflus F, Nanje A, Gutekunst C-A, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington\u2019s disease transgenic mice. Neurobiol Dis 17(2):319\u2013325","journal-title":"Neurobiol Dis"},{"issue":"3","key":"8316_CR288","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/nbdi.2002.0562","volume":"11","author":"OA Andreassen","year":"2002","unstructured":"Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK (2002) Huntington\u2019s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11(3):410\u2013424","journal-title":"Neurobiol Dis"},{"issue":"2","key":"8316_CR289","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2826.2007.01629.x","volume":"20","author":"K Josefsen","year":"2008","unstructured":"Josefsen K, Nielsen MD, J\u00f8rgensen KH, Bock T, N\u00f8rrem\u00f8lle A, S\u00f8rensen SA, Naver B, Hasholt L (2008) Impaired glucose tolerance in the R6\/1 transgenic mouse model of Huntington\u2019s disease. J Neuroendocrinol 20(2):165\u2013172","journal-title":"J Neuroendocrinol"},{"issue":"13","key":"8316_CR290","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","volume":"14","author":"AD Strand","year":"2005","unstructured":"Strand AD, Aragaki AK, Shaw D et al (2005) Gene expression in Huntington\u2019s disease skeletal muscle: a potential biomarker. Hum Mol Genet 14(13):1863\u20131876","journal-title":"Hum Mol Genet"},{"issue":"2","key":"8316_CR291","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","volume":"166","author":"MJ Hunt","year":"2005","unstructured":"Hunt MJ, Morton AJ (2005) Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington\u2019s disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166(2):220\u2013229","journal-title":"Exp Brain Res"},{"issue":"2","key":"8316_CR292","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1152\/japplphysiol.01219.2001","volume":"93","author":"EJ Henriksen","year":"2002","unstructured":"Henriksen EJ (2002) Invited review: Effects of acute exercise and exercise training on insulin resistance. J Appl Physiol 93(2):788\u2013796","journal-title":"J Appl Physiol"},{"issue":"2","key":"8316_CR293","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","volume":"411","author":"TC Ma","year":"2007","unstructured":"Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR (2007) Metformin therapy in a transgenic mouse model of Huntington\u2019s disease. Neurosci Lett 411(2):98\u2013103","journal-title":"Neurosci Lett"},{"issue":"2","key":"8316_CR294","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/db08-0799","volume":"58","author":"B Martin","year":"2009","unstructured":"Martin B, Golden E, Carlson OD et al (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease. Diabetes 58(2):318\u2013328","journal-title":"Diabetes"},{"issue":"2","key":"8316_CR295","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","volume":"8","author":"MV Karpuj","year":"2002","unstructured":"Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8(2):143\u2013149","journal-title":"Nat Med"},{"issue":"20","key":"8316_CR296","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","volume":"22","author":"A Dedeoglu","year":"2002","unstructured":"Dedeoglu A, Kubilus JK, Jeitner TM et al (2002) Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease. J Neurosci 22(20):8942\u20138950","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"8316_CR297","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2004.12.011","volume":"231","author":"X Wang","year":"2005","unstructured":"Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, Saint-Pierre M, Brownell A-L (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6\/2 mouse model of Huntington\u2019s disease. J Neurol Sci 231(1\u20132):57\u201366","journal-title":"J Neurol Sci"},{"issue":"1","key":"8316_CR298","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","volume":"95","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 95(1):210\u2013220","journal-title":"J Neurochem"},{"issue":"9","key":"8316_CR299","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401093","volume":"9","author":"PG Mastroberardino","year":"2002","unstructured":"Mastroberardino PG, Iannicola C, Nardacci R et al (2002) \u201cTissue\u201d transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington\u2019s disease. Cell Death Differ 9(9):873\u2013880","journal-title":"Cell Death Differ"},{"issue":"9","key":"8316_CR300","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/emmm.201000084","volume":"2","author":"SJ McConoughey","year":"2010","unstructured":"McConoughey SJ, Basso M, Niatsetskaya ZV et al (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2(9):349\u2013370","journal-title":"EMBO Mol Med"},{"issue":"1","key":"8316_CR301","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","volume":"25","author":"AJ Morton","year":"2005","unstructured":"Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington\u2019s disease. J Neurosci 25(1):157\u2013163","journal-title":"J Neurosci"},{"issue":"2","key":"8316_CR302","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12311-011-0252-7","volume":"10","author":"JL Pedroso","year":"2011","unstructured":"Pedroso JL, Braga-Neto P, Fel\u00edcio AC, Dutra LA, Santos WAC, do Prado GF, Barsottini OGP (2011) Sleep disorders in machado-joseph disease: frequency, discriminative thresholds, predictive values, and correlation with ataxia-related motor and non-motor features. Cerebellum 10(2):291\u2013295","journal-title":"Cerebellum"},{"issue":"2","key":"8316_CR303","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","volume":"30","author":"J Hara","year":"2001","unstructured":"Hara J, Beuckmann CT, Nambu T et al (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30(2):345\u2013354","journal-title":"Neuron"},{"key":"8316_CR304","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.brainres.2009.03.072","volume":"1279","author":"PN Pallier","year":"2009","unstructured":"Pallier PN, Morton AJ (2009) Management of sleep\/wake cycles improves cognitive function in a transgenic mouse model of Huntington\u2019s disease. Brain Res 1279:90\u201398","journal-title":"Brain Res"},{"issue":"29","key":"8316_CR305","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1523\/JNEUROSCI.0649-07.2007","volume":"27","author":"PN Pallier","year":"2007","unstructured":"Pallier PN, Maywood ES, Zheng Z, Chesham JE, Inyushkin AN, Dyball R, Hastings MH, Morton AJ (2007) Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington\u2019s disease. J Neurosci 27(29):7869\u20137878","journal-title":"J Neurosci"},{"issue":"3","key":"8316_CR306","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nbd.2007.01.006","volume":"26","author":"JM Raamsdonk Van","year":"2007","unstructured":"Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26(3):512\u2013520","journal-title":"Neurobiol Dis"},{"issue":"5","key":"8316_CR307","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35(5):843\u2013854","journal-title":"Neuron"},{"issue":"6","key":"8316_CR308","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nm878","volume":"9","author":"M Katsuno","year":"2003","unstructured":"Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9(6):768\u2013773","journal-title":"Nat Med"},{"issue":"20","key":"8316_CR309","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1523\/JNEUROSCI.0808-04.2004","volume":"24","author":"ES Chevalier-Larsen","year":"2004","unstructured":"Chevalier-Larsen ES, O\u2019Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, Merry DE (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24(20):4778\u20134786","journal-title":"J Neurosci"},{"issue":"10","key":"8316_CR310","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/1389450111007011237","volume":"11","author":"S Hult","year":"2010","unstructured":"Hult S, Schultz K, Soylu R, Peters\u00e9n A (2010) Hypothalamic and neuroendocrine changes in Huntington\u2019s disease. Curr Drug Targets 11(10):1237\u20131249","journal-title":"Curr Drug Targets"},{"issue":"3","key":"8316_CR311","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493\u2013506","journal-title":"Cell"},{"issue":"3","key":"8316_CR312","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8(3):397\u2013407","journal-title":"Hum Mol Genet"},{"issue":"12","key":"8316_CR313","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","volume":"285","author":"C Landles","year":"2010","unstructured":"Landles C, Sathasivam K, Weiss A et al (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285(12):8808\u20138823","journal-title":"J Biol Chem"},{"issue":"1","key":"8316_CR314","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","volume":"23","author":"JG Hodgson","year":"1999","unstructured":"Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington\u2019s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181\u2013192","journal-title":"Neuron"},{"issue":"13","key":"8316_CR315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow EJ, van Raamsdonk J, Rogers D et al (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555\u20131567","journal-title":"Hum Mol Genet"},{"issue":"2\u20133","key":"8316_CR316","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainresbull.2010.05.005","volume":"88","author":"S Brooks","year":"2012","unstructured":"Brooks S, Higgs G, Janghra N, Jones L, Dunnett SB (2012) Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL\/6\u00a0J) Huntington\u2019s disease transgenic mice. Brain Res Bull 88(2\u20133):113\u2013120","journal-title":"Brain Res Bull"},{"issue":"6","key":"8316_CR317","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","volume":"1792","author":"RJ Ferrante","year":"2009","unstructured":"Ferrante RJ (2009) Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 1792(6):506\u2013520","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"8316_CR318","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","volume":"465","author":"LB Menalled","year":"2003","unstructured":"Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet M-F (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats. J Comp Neurol 465(1):11\u201326","journal-title":"J Comp Neurol"},{"issue":"4","key":"8316_CR319","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/9.4.503","volume":"9","author":"VC Wheeler","year":"2000","unstructured":"Wheeler VC, White JK, Gutekunst CA et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9(4):503\u2013513","journal-title":"Hum Mol Genet"},{"issue":"24","key":"8316_CR320","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182\u20136195","journal-title":"J Neurosci"},{"issue":"3","key":"8316_CR321","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1471-4159.2005.03035.x","volume":"93","author":"S Kotliarova","year":"2005","unstructured":"Kotliarova S, Jana NR, Sakamoto N et al (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 93(3):641\u2013653","journal-title":"J Neurochem"},{"issue":"1","key":"8316_CR322","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000321712","volume":"36","author":"T Hoppitt","year":"2011","unstructured":"Hoppitt T, Pall H, Calvert M, Gill P, Yao G, Ramsay J, James G, Conduit J, Sackley C (2011) A systematic review of the incidence and prevalence of long-term neurological conditions in the UK. Neuroepidemiology 36(1):19\u201328","journal-title":"Neuroepidemiology"},{"issue":"2","key":"8316_CR323","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12311-008-0023-2","volume":"7","author":"T Klockgether","year":"2008","unstructured":"Klockgether T (2008) The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum 7(2):101\u2013105","journal-title":"Cerebellum"},{"issue":"6","key":"8316_CR324","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0092-8674(95)90273-2","volume":"82","author":"EN Burright","year":"1995","unstructured":"Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82(6):937\u2013948","journal-title":"Cell"},{"issue":"6","key":"8316_CR325","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0896-6273(02)00733-X","volume":"34","author":"K Watase","year":"2002","unstructured":"Watase K, Weeber EJ, Xu B et al (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34(6):905\u2013919","journal-title":"Neuron"},{"issue":"3","key":"8316_CR326","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0896-6273(02)01190-X","volume":"37","author":"SY Yoo","year":"2003","unstructured":"Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, Chen S, Armstrong DL, Wu SM, Sweatt JD, Zoghbi HY (2003) SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37(3):383\u2013401","journal-title":"Neuron"},{"issue":"4","key":"8316_CR327","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/hmg\/ddn403","volume":"18","author":"T Sato","year":"2009","unstructured":"Sato T, Miura M, Yamada M et al (2009) Severe neurological phenotypes of Q129 DRPLA transgenic mice serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum Mol Genet 18(4):723\u2013736","journal-title":"Hum Mol Genet"},{"issue":"6","key":"8316_CR328","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0278-5846(86)90051-5","volume":"10","author":"P Willner","year":"1986","unstructured":"Willner P (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10(6):677\u2013690","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"8316_CR329","first-page":"1","volume-title":"Methods for assessing the validity of animals models of human psychopathology","author":"P Willner","year":"1991","unstructured":"Willner P (1991) Methods for assessing the validity of animals models of human psychopathology. Animal models in psychiatry. The Humana Press Inc., Clifton, pp 1\u201324"},{"issue":"1","key":"8316_CR330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.06.005","volume":"32","author":"MY Heng","year":"2008","unstructured":"Heng MY, Detloff PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32(1):1\u20139","journal-title":"Neurobiol Dis"},{"key":"8316_CR331","volume-title":"Huntington\u2019s disease, clinical experimental therapeutics. Neurobiology of Huntington\u2019s disease: applications to drug discovery","author":"R Dorsey","year":"2011","unstructured":"Dorsey R, Shoulson I (2011) Huntington\u2019s disease, clinical experimental therapeutics. Neurobiology of Huntington\u2019s disease: applications to drug discovery. CRC Press, Boca Raton"},{"issue":"1","key":"8316_CR332","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/exnr.1998.6926","volume":"154","author":"SB Dunnett","year":"1998","unstructured":"Dunnett SB, Carter RJ, Watts C, Torres EM, Mahal A, Mangiarini L, Bates G, Morton AJ (1998) Striatal transplantation in a transgenic mouse model of Huntington\u2019s disease. Exp Neurol 154(1):31\u201340","journal-title":"Exp Neurol"},{"issue":"1\u20132","key":"8316_CR333","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0006-8993(00)02640-8","volume":"875","author":"AW Deckel","year":"2000","unstructured":"Deckel AW, Volmer P, Weiner R, Gary KA, Covault J, Sasso D, Schmerler N, Watts D, Yan Z, Abeles I (2000) Dietary arginine alters time of symptom onset in Huntington\u2019s disease transgenic mice. Brain Res 875(1\u20132):187\u2013195","journal-title":"Brain Res"},{"issue":"1\u20132","key":"8316_CR334","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0006-8993(02)02550-7","volume":"939","author":"AW Deckel","year":"2002","unstructured":"Deckel AW, Tang V, Nuttal D, Gary K, Elder R (2002) Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington\u2019s disease transgenic mice. Brain Res 939(1\u20132):76\u201386","journal-title":"Brain Res"},{"issue":"3\u20134","key":"8316_CR335","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0361-9230(01)00655-4","volume":"56","author":"A Dellen van","year":"2001","unstructured":"van Dellen A, Deacon R, York D, Blakemore C, Hannan AJ (2001) Anterior cingulate cortical transplantation in transgenic Huntington\u2019s disease mice. Brain Res Bull 56(3\u20134):313\u2013318","journal-title":"Brain Res Bull"},{"issue":"1","key":"8316_CR336","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","volume":"109","author":"JJ Clifford","year":"2002","unstructured":"Clifford JJ, Drago J, Natoli AL, Wong JYF, Kinsella A, Waddington JL, Vaddadi KS (2002) Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington\u2019s disease. Neuroscience 109(1):81\u201388","journal-title":"Neuroscience"},{"issue":"4","key":"8316_CR337","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","volume":"17","author":"J Schiefer","year":"2002","unstructured":"Schiefer J, Landwehrmeyer GB, L\u00fcesse H-G, Spr\u00fcnken A, Puls C, Milkereit A, Milkereit E, Kosinski CM (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington\u2019s disease. Mov Disord 17(4):748\u2013757","journal-title":"Mov Disord"},{"key":"8316_CR338","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2202-5-17","volume":"5","author":"JMAC Gil","year":"2004","unstructured":"Gil JMAC, Leist M, Popovic N, Brundin P, Peters\u00e9n A (2004) Asialoerythropoietin is not effective in the R6\/2 line of Huntington\u2019s disease mice. BMC Neurosci 5:17","journal-title":"BMC Neurosci"},{"issue":"2","key":"8316_CR339","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00210-004-0959-9","volume":"370","author":"B Zucker","year":"2004","unstructured":"Zucker B, Ludin DE, Gerds TA, L\u00fccking CH, Landwehrmeyer GB, Feuerstein TJ (2004) Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol 370(2):131\u2013139","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"8316_CR340","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1460-9568.2005.03895.x","volume":"21","author":"AJ Morton","year":"2005","unstructured":"Morton AJ, Hunt MJ, Hodges AK, Lewis PD, Redfern AJ, Dunnett SB, Jones L (2005) A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington\u2019s disease. Eur J Neurosci 21(4):855\u2013870","journal-title":"Eur J Neurosci"},{"issue":"33","key":"8316_CR341","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","volume":"102","author":"T Nguyen","year":"2005","unstructured":"Nguyen T, Hamby A, Massa SM (2005) Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102(33):11840\u201311845","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8316_CR342","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.expneurol.2005.07.021","volume":"196","author":"JM Raamsdonk Van","year":"2005","unstructured":"Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196(2):266\u2013272","journal-title":"Exp Neurol"},{"issue":"6","key":"8316_CR343","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.neurobiolaging.2005.04.001","volume":"27","author":"CDC Bailey","year":"2006","unstructured":"Bailey CDC, Johnson GVW (2006) The protective effects of cystamine in the R6\/2 Huntington\u2019s disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 27(6):871\u2013879","journal-title":"Neurobiol Aging"},{"issue":"1","key":"8316_CR344","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/hmg\/ddi423","volume":"15","author":"JS Bett","year":"2006","unstructured":"Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP (2006) Proteasome impairment does not contribute to pathogenesis in R6\/2 Huntington\u2019s disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 15(1):33\u201344","journal-title":"Hum Mol Genet"},{"issue":"24","key":"8316_CR345","doi-asserted-by":"crossref","first-page":"16672","DOI":"10.1074\/jbc.M511648200","volume":"281","author":"Z Qiu","year":"2006","unstructured":"Qiu Z, Norflus F, Singh B et al (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 281(24):16672\u201316680","journal-title":"J Biol Chem"},{"issue":"5\u20136","key":"8316_CR346","first-page":"485","volume":"25","author":"ND Dey","year":"2007","unstructured":"Dey ND, Boersen AJ, Myers RA, York LR, Bombard MC, Lu M, Sandstrom MI, Hulce VD, Lescaudron L, Dunbar GL (2007) The novel substituted pyrimidine, KP544, reduces motor deficits in the R6\/2 transgenic mouse model of Huntington\u2019s disease. Restor Neurol Neurosci 25(5\u20136):485\u2013492","journal-title":"Restor Neurol Neurosci"},{"issue":"2\u20133","key":"8316_CR347","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainresbull.2006.10.017","volume":"72","author":"D Glynn","year":"2007","unstructured":"Glynn D, Reim K, Brose N, Morton AJ (2007) Depletion of Complexin II does not affect disease progression in a mouse model of Huntington\u2019s disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. Brain Res Bull 72(2\u20133):108\u2013120","journal-title":"Brain Res Bull"},{"issue":"3","key":"8316_CR348","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.nbd.2006.11.002","volume":"25","author":"K Merienne","year":"2007","unstructured":"Merienne K, Friedman J, Akimoto M, Abou-Sleymane G, Weber C, Swaroop A, Trottier Y (2007) Preventing polyglutamine-induced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy. Neurobiol Dis 25(3):571\u2013581","journal-title":"Neurobiol Dis"},{"issue":"47","key":"8316_CR349","doi-asserted-by":"crossref","first-page":"12908","DOI":"10.1523\/JNEUROSCI.4318-07.2007","volume":"27","author":"EC Stack","year":"2007","unstructured":"Stack EC, Dedeoglu A, Smith KM et al (2007) Neuroprotective effects of synaptic modulation in Huntington\u2019s disease R6\/2 mice. J Neurosci 27(47):12908\u201312915","journal-title":"J Neurosci"},{"issue":"3","key":"8316_CR350","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nm1547","volume":"13","author":"Z Yang","year":"2007","unstructured":"Yang Z, Chang Y-J, Yu I-C et al (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13(3):348\u2013353","journal-title":"Nat Med"},{"issue":"9","key":"8316_CR351","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/hmg\/ddm057","volume":"16","author":"A Zourlidou","year":"2007","unstructured":"Zourlidou A, Gidalevitz T, Kristiansen M et al (2007) Hsp27 overexpression in the R6\/2 mouse model of Huntington\u2019s disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet 16(9):1078\u20131090","journal-title":"Hum Mol Genet"},{"issue":"1","key":"8316_CR352","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.expneurol.2008.05.015","volume":"213","author":"S Cipriani","year":"2008","unstructured":"Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F (2008) Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 213(1):163\u2013170","journal-title":"Exp Neurol"},{"issue":"48","key":"8316_CR353","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1523\/JNEUROSCI.3909-08.2008","volume":"28","author":"X Chen","year":"2008","unstructured":"Chen X, Tang T-S, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I (2008) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci 28(48):12713\u201312724","journal-title":"J Neurosci"},{"issue":"42","key":"8316_CR354","doi-asserted-by":"crossref","first-page":"13126","DOI":"10.1523\/JNEUROSCI.0647-09.2009","volume":"29","author":"S Chintawar","year":"2009","unstructured":"Chintawar S, Hourez R, Ravella A, Gall D, Orduz D, Rai M, Bishop DP, Geuna S, Schiffmann SN, Pandolfo M (2009) Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J Neurosci 29(42):13126\u201313135","journal-title":"J Neurosci"},{"issue":"37","key":"8316_CR355","doi-asserted-by":"crossref","first-page":"11550","DOI":"10.1523\/JNEUROSCI.3307-09.2009","volume":"29","author":"Y Dai","year":"2009","unstructured":"Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA (2009) Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6\/2 mouse model of Huntington\u2019s disease. J Neurosci 29(37):11550\u201311559","journal-title":"J Neurosci"},{"issue":"6","key":"8316_CR356","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","volume":"4","author":"CL Benn","year":"2009","unstructured":"Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP (2009) Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 4(6):e5747","journal-title":"PLoS One"},{"issue":"5","key":"8316_CR357","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21788","volume":"66","author":"S-T Lee","year":"2009","unstructured":"Lee S-T, Chu K, Jung K-H et al (2009) Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 66(5):671\u2013681","journal-title":"Ann Neurol"},{"issue":"3","key":"8316_CR358","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","volume":"36","author":"M Li","year":"2009","unstructured":"Li M, Huang Y, Ma AAK, Lin E, Diamond MI (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice. Neurobiol Dis 36(3):413\u2013420","journal-title":"Neurobiol Dis"},{"issue":"29","key":"8316_CR359","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1523\/JNEUROSCI.0660-09.2009","volume":"29","author":"J Liu","year":"2009","unstructured":"Liu J, Tang T-S, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I (2009) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 29(29):9148\u20139162","journal-title":"J Neurosci"},{"issue":"3","key":"8316_CR360","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuron.2009.07.019","volume":"63","author":"I Palazzolo","year":"2009","unstructured":"Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63(3):316\u2013328","journal-title":"Neuron"},{"issue":"Pt 4","key":"8316_CR361","first-page":"919","volume":"132","author":"MA Pouladi","year":"2009","unstructured":"Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Peters\u00e9n A, Hayden MR (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132(Pt 4):919\u2013932","journal-title":"Brain"},{"issue":"1","key":"8316_CR362","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neulet.2009.01.040","volume":"452","author":"SJ Tallaksen-Greene","year":"2009","unstructured":"Tallaksen-Greene SJ, Janiszewska A, Benton K, Hou G, Dick R, Brewer GJ, Albin RL (2009) Evaluation of tetrathiomolybdate in the R6\/2 model of Huntington disease. Neurosci Lett 452(1):60\u201362","journal-title":"Neurosci Lett"},{"issue":"5","key":"8316_CR363","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1523\/JNEUROSCI.4411-08.2009","volume":"29","author":"T-S Tang","year":"2009","unstructured":"Tang T-S, Guo C, Wang H, Chen X, Bezprozvanny I (2009) Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington\u2019s disease mouse model. J Neurosci 29(5):1257\u20131266","journal-title":"J Neurosci"},{"issue":"9","key":"8316_CR364","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00702-009-0253-6","volume":"116","author":"E Vamos","year":"2009","unstructured":"Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P (2009) Neuroprotective effects of probenecid in a transgenic animal model of Huntington\u2019s disease. J Neural Transm 116(9):1079\u20131086","journal-title":"J Neural Transm"},{"issue":"3","key":"8316_CR365","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nbt.1608","volume":"28","author":"PO Bauer","year":"2010","unstructured":"Bauer PO, Goswami A, Wong HK et al (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 28(3):256\u2013263","journal-title":"Nat Biotechnol"},{"issue":"1","key":"8316_CR366","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.expneurol.2010.07.022","volume":"226","author":"M Decressac","year":"2010","unstructured":"Decressac M, Wright B, Tyers P, Gaillard A, Barker RA (2010) Neuropeptide Y modifies the disease course in the R6\/2 transgenic model of Huntington\u2019s disease. Exp Neurol 226(1):24\u201332","journal-title":"Exp Neurol"},{"issue":"2","key":"8316_CR367","doi-asserted-by":"crossref","first-page":"e9347","DOI":"10.1371\/journal.pone.0009347","volume":"5","author":"BR Snyder","year":"2010","unstructured":"Snyder BR, Chiu AM, Prockop DJ, Chan AWS (2010) Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington\u2019s disease. PLoS One 5(2):e9347","journal-title":"PLoS One"},{"key":"8316_CR368","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1750-1326-6-81","volume":"6","author":"X Chen","year":"2011","unstructured":"Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I (2011) Dantrolene is neuroprotective in Huntington\u2019s disease transgenic mouse model. Mol Neurodegener 6:81","journal-title":"Mol Neurodegener"},{"issue":"2","key":"8316_CR369","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.expneurol.2011.06.016","volume":"231","author":"AI Duarte","year":"2011","unstructured":"Duarte AI, Petit GH, Ranganathan S, Li J-Y, Oliveira CR, Brundin P, Bj\u00f6rkqvist M, Rego AC (2011) IGF-1 protects against diabetic features in an in vivo model of Huntington\u2019s disease. Exp Neurol 231(2):314\u2013319","journal-title":"Exp Neurol"},{"issue":"33","key":"8316_CR370","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1523\/JNEUROSCI.0905-11.2011","volume":"31","author":"R Hourez","year":"2011","unstructured":"Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d\u2019Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN (2011) Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 31(33):11795\u201311807","journal-title":"J Neurosci"},{"issue":"5","key":"8316_CR371","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1073\/pnas.1018748108","volume":"108","author":"P Jafar-Nejad","year":"2011","unstructured":"Jafar-Nejad P, Ward CS, Richman R, Orr HT, Zoghbi HY (2011) Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci U S A 108(5):2142\u20132147","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"8316_CR372","doi-asserted-by":"crossref","first-page":"e24620","DOI":"10.1371\/journal.pone.0024620","volume":"6","author":"S Lim","year":"2011","unstructured":"Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, Tieu K (2011) D-\u03b2-hydroxybutyrate is protective in mouse models of Huntington\u2019s disease. PLoS One 6(9):e24620","journal-title":"PLoS One"},{"issue":"4","key":"8316_CR373","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI43220","volume":"121","author":"Y-S Lin","year":"2011","unstructured":"Lin Y-S, Chen C-M, Soong B et al (2011) Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J Clin Invest 121(4):1519\u20131523","journal-title":"J Clin Invest"},{"issue":"8","key":"8316_CR374","doi-asserted-by":"crossref","first-page":"e22924","DOI":"10.1371\/journal.pone.0022924","volume":"6","author":"Y-T Lin","year":"2011","unstructured":"Lin Y-T, Chern Y, Shen C-KJ, Wen H-L, Chang Y-C, Li H, Cheng T-H, Hsieh-Li HM (2011) Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington\u2019s disease mouse models. PLoS One 6(8):e22924","journal-title":"PLoS One"},{"issue":"2","key":"8316_CR375","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/hmg\/ddq460","volume":"20","author":"P Maher","year":"2011","unstructured":"Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet 20(2):261\u2013270","journal-title":"Hum Mol Genet"},{"issue":"4","key":"8316_CR376","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/hmg\/ddq512","volume":"20","author":"MR Mughal","year":"2011","unstructured":"Mughal MR, Baharani A, Chigurupati S, Son TG, Chen E, Yang P, Okun E, Arumugam T, Chan SL, Mattson MP (2011) Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice. Hum Mol Genet 20(4):659\u2013669","journal-title":"Hum Mol Genet"},{"issue":"6","key":"8316_CR377","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","volume":"6","author":"A Bobrowska","year":"2011","unstructured":"Bobrowska A, Paganetti P, Matthias P, Bates GP (2011) Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 6(6):e20696","journal-title":"PLoS One"},{"issue":"10","key":"8316_CR378","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1172\/JCI46305","volume":"121","author":"M Sadagurski","year":"2011","unstructured":"Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF (2011) IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121(10):4070\u20134081","journal-title":"J Clin Invest"},{"key":"8316_CR379","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1423-0127-18-54","volume":"18","author":"Y-K Chang","year":"2011","unstructured":"Chang Y-K, Chen M-H, Chiang Y-H, Chen Y-F, Ma W-H, Tseng C-Y, Soong B-W, Ho JH, Lee OK (2011) Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells. J Biomed Sci 18:54","journal-title":"J Biomed Sci"},{"issue":"2","key":"8316_CR380","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12311-011-0262-5","volume":"10","author":"PJS Vig","year":"2011","unstructured":"Vig PJS, Hearst S, Shao Q, Lopez ME, Murphy HA 2nd, Safaya E (2011) Glial S100B protein modulates mutant Ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy. Cerebellum 10(2):254\u2013266","journal-title":"Cerebellum"},{"issue":"41","key":"8316_CR381","doi-asserted-by":"crossref","first-page":"14496","DOI":"10.1523\/JNEUROSCI.3059-11.2011","volume":"31","author":"X Wang","year":"2011","unstructured":"Wang X, Sirianni A, Pei Z et al (2011) The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31(41):14496\u201314507","journal-title":"J Neurosci"},{"key":"8316_CR382","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1038\/cddis.2010.94","volume":"2","author":"S Zhu","year":"2011","unstructured":"Zhu S, Zhang Y, Bai G, Li H (2011) Necrostatin-1 ameliorates symptoms in R6\/2 transgenic mouse model of Huntington\u2019s disease. Cell Death Dis 2:e115","journal-title":"Cell Death Dis"},{"issue":"2","key":"8316_CR383","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1471-4159.2011.07304.x","volume":"118","author":"Y-C Chang","year":"2011","unstructured":"Chang Y-C, Lin C-Y, Hsu C-M, Lin H-C, Chen Y-H, Lee-Chen G-J, Su M-T, Ro L-S, Chen C-M, Hsieh-Li HM (2011) Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17. J Neurochem 118(2):288\u2013303","journal-title":"J Neurochem"},{"issue":"1","key":"8316_CR384","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mcn.2011.03.003","volume":"47","author":"KA Chen","year":"2011","unstructured":"Chen KA, Cruz PE, Lanuto DJ, Flotte TR, Borchelt DR, Srivastava A, Zhang J, Steindler DA, Zheng T (2011) Cellular fusion for gene delivery to SCA1 affected Purkinje neurons. Mol Cell Neurosci 47(1):61\u201370","journal-title":"Mol Cell Neurosci"},{"issue":"9","key":"8316_CR385","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.chembiol.2011.06.010","volume":"18","author":"X Chen","year":"2011","unstructured":"Chen X, Wu J, Luo Y et al (2011) Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington\u2019s disease. Chem Biol 18(9):1113\u20131125","journal-title":"Chem Biol"},{"issue":"9","key":"8316_CR386","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"A Pardo Di","year":"2012","unstructured":"Di Pardo A, Maglione V, Alpaugh M et al (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109(9):3528\u20133533","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8316_CR387","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","volume":"32","author":"W Kwan","year":"2012","unstructured":"Kwan W, Magnusson A, Chou A et al (2012) Bone marrow transplantation confers modest benefits in mouse models of Huntington\u2019s disease. J Neurosci 32(1):133\u2013142","journal-title":"J Neurosci"},{"issue":"2","key":"8316_CR388","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","volume":"7","author":"L Moumn\u00e9","year":"2012","unstructured":"Moumn\u00e9 L, Campbell K, Howland D, Ouyang Y, Bates GP (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington\u2019s disease. PLoS One 7(2):e31080","journal-title":"PLoS One"},{"issue":"2","key":"8316_CR389","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neures.2012.03.001","volume":"73","author":"S Noma","year":"2012","unstructured":"Noma S, Ohya-Shimada W, Kanai M, Ueda K, Nakamura T, Funakoshi H (2012) Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7. Neurosci Res 73(2):115\u201321","journal-title":"Neurosci Res"},{"issue":"6","key":"8316_CR390","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of Huntingtin synthesis. Neuron 74(6):1031\u20131044","journal-title":"Neuron"},{"key":"8316_CR391","doi-asserted-by":"crossref","unstructured":"Pouladi MA, Brillaud E, Xie Y et al (2012) NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis. doi: 10.1016\/j.nbd.2012.06.026","DOI":"10.1016\/j.nbd.2012.06.026"},{"issue":"53","key":"8316_CR392","doi-asserted-by":"crossref","first-page":"55969","DOI":"10.1074\/jbc.M409062200","volume":"279","author":"D Helmlinger","year":"2004","unstructured":"Helmlinger D, Bonnet J, Mandel J-L, Trottier Y, Devys D (2004) Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. J Biol Chem 279(53):55969\u201355977","journal-title":"J Biol Chem"},{"issue":"Pt 4","key":"8316_CR393","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/brain\/aws022","volume":"135","author":"J Labbadia","year":"2012","unstructured":"Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain: A Journal of Neurology 135(Pt 4):1180\u201396","journal-title":"Brain: A Journal of Neurology"},{"issue":"1","key":"8316_CR394","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.expneurol.2010.03.005","volume":"224","author":"AD Ebert","year":"2010","unstructured":"Ebert AD, Barber AE, Heins BM, Svendsen CN (2010) Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington\u2019s disease. Exp Neurol 224(1):155\u2013162","journal-title":"Exp Neurol"},{"issue":"1","key":"8316_CR395","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.expneurol.2004.12.009","volume":"193","author":"N Popovic","year":"2005","unstructured":"Popovic N, Maingay M, Kirik D, Brundin P (2005) Lentiviral gene delivery of GDNF into the striatum of R6\/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193(1):65\u201374","journal-title":"Exp Neurol"},{"issue":"11","key":"8316_CR396","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nm.2494","volume":"17","author":"M Cvetanovic","year":"2011","unstructured":"Cvetanovic M, Patel JM, Marti HH, Kini AR, Opal P (2011) Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med 17(11):1445\u20131447","journal-title":"Nat Med"},{"issue":"11","key":"8316_CR397","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","volume":"6","author":"M Mielcarek","year":"2011","unstructured":"Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease. PLoS One 6(11):e27746","journal-title":"PLoS One"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12035-012-8316-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T21:58:00Z","timestamp":1714341480000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-012-8316-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,4]]},"references-count":397,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["8316"],"URL":"https:\/\/doi.org\/10.1007\/s12035-012-8316-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,4]]}}}